Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data
Conditions: Antiplatelet
Sponsor: Brigham and Women's Hospital

Replication of Ticagrelor versus Clopidogrel in Patients with 
Acute Coronary Syndromes (PLATO Trial)
January 13, 2020

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
1 
 
1. RCT Details 
This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely 
as possible given the remaining limitations inherent in the healthcare databases.  
 
1.1 Title 
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes (PLATO trial) 
 
1.2 Intended aim(s) 
 
Compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 
mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute 
coronary syndrome, with or without ST-segment elevation. 
 
1.3 Primary endpoint for replication and RCT finding 
 
a composite of death from vascular causes, myocardial infarction, or stroke 
 
1.4 Required power for primary endpoint and noninferiority margin (if applicable) 
 
Estimated that 1780 such events would be required to achieve 90% power to detect a relative risk reduction of 13.5% in the 
rate of the primary end point in the ticagrelor group as compared with the clopidogrel group, given an event rate of 11% in 
the clopidogrel group at 12 months. 
 
1.5 Primary trial estimate targeted for replication 
 
HR = 0.84 (95% CI 0.77–0.92) comparing ticagrelor to clopidogrel (Wallentin et al., 2009) 
 
2. Person responsible for implementation of replication in Aetion 
Ajinkya Pawar, Ph.D. implemented the study design in the Aetion Evidence Platform. S/he is not responsible for the validity of the 
design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform.   
 
 
3. Data Source(s) 
United/Optum, MarketScan 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
2 
 
4. Study Design Diagram 
The study design diagram visualizes key aspects of the longitudinal study design for expedited review. 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
3 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
4 
 
5. Cohort Identification  
 
5.1 Cohort Summary 
This study will involve a new user, parallel group, cohort study design comparing ticagrelor 90mg twice daily to clopidogrel 75mg 
daily. The patients will be required to have continuous enrollment during the baseline period of 180 days before initiation of 
ticagrelor 90mg or the comparator drug (cohort entry date). Follow-up for the outcome (3P-MACE), begins the day after drug 
initiation.  
 
 
5.2 Important steps for cohort formation 
 New users (defined as no use in 180 days prior to index date) of an exposure and a comparator drug will be identified. 
 
5.2.1 Eligible cohort entry dates 
Market availability of ticagrelor in the U.S. started on 2011-07-20.       
• For Marketscan: 2011-07-20 to 2017-12-31 (end of data availability).  
• For Optum: 2011-07-20 to 2019-03-31 (end of data availability). 
 
5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date 
 
Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided 
in Appendix A and are summarized in the flowcharts below.   
 
5.3 Flowchart of the study cohort assembly 
 
  
Optum 
MarketScan 
Less Excluded Patients 
Less Excluded 
Patients 
Remaining 
Patients 
Less Excluded Patients 
Remaining 
Patients 
All patients 
  
75,524,500 
  
191,990,035 
Met cohort entry criteria: 
Patients with hospitalization for potential ST-segment elevation or non-ST segment 
elevation Acute Coronary Syndrome  
-75275676 
248,824 
-191715444 
274,591 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
5 
Patients with sufficient enrollment period in the claims database 
-33452 
215,372 
-67391 
207,200 
Parent: Excluded based on Start of Clopidogrel 75mg OR Ticagrelor 90mg (if never 
began 14 days after discharge) 
-136791 
78,581 
-119212 
87,988 
Parent: Excluded based on Enrollment with allowed gap- from hospital discharge to 14 
days after discharge 
-610 
77,971 
-1431 
86,557 
Parent: Final cohort 
  
77,971 
  
86,557 
Patients who initiate clopidogrel 75mg or ticagrelor 90mg 14 days within discharge 
from the ACS hospitalization  
-245 
77,726 
-23 
86,534 
Patients with sufficient enrollment period covering post 14 days hospital discharge.  
0 
77,726 
0 
86,534 
Patients with no prior use of clopidogrel  
-5415 
72,311 
-4841 
81,693 
Patients with no prior use of ticagrelor  
-842 
71,469 
-799 
80,894 
Patients without qualification in >1 exposure category  
-46 
71,423 
-44 
80,850 
Patients with age 18 or older  
0 
71,423 
-1 
80,849 
Patients with risk factors such as age >=60, previous MI, CABG, TIA, Carotid stenosis, 
cerebral revascularizations, diabetes mellitus, peripheral artery disease, chronic renal 
dysfunction  
-16839 
54,584 
-22689 
58,160 
Patients without contraindication to clopidogrel: moderate/severe liver disease 180 
days prior to drug initiation 
-3508 
51,076 
-2609 
55,551 
Patients without contraindication to clopidogrel: active bleeding or bleeding history 
180 days prior to drug initiation 
-978 
50,098 
-2631 
52,920 
Patients without contraindication to clopidogrel: major surgery 30 days prior to drug 
initiation 
-549 
49,549 
-482 
52,438 
Patients not on concomitant oral/IV therapy with CYP3A inhibitors 90 days prior to 
drug initiation 
-1011 
48,538 
-1010 
51,428 
Patients who do not require dialysis 180 days prior to drug initiation  
-654 
47,884 
-457 
50,971 
Patients without clinically significant thrombocytopenia 180 days prior to drug 
initiation  
-1108 
46,776 
-1396 
49,575 
Patients without clinically significant anemia 180 days prior to drug initiation 
-3559 
43,217 
-4869 
44,706 
Excluded based on Exclusion #11 - Any other condition that may put the patient at risk- 
180 days prior to drug initiation 
Patients without conditions that put individuals at risk or influence study results such 
as cardiogenic shock, severe hemodynamic instability, or active cancer 180 days prior 
to drug initiation.  
-1764 
41,453 
-3848 
40,858 
Excluded based on Exclusion #13 - Pregnancy- 180 days prior to drug initiation 
Patients not pregnant  
-7 
41,446 
-9 
40,849 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
6 
Final cohort 
  
41,446 
  
40,849 
 
 
6. Variables  
 
6.1 Exposure-related variables:  
 
Study drug:  
The study exposure of interest is initiation of ticagrelor. Initiation will be defined as starting treatment with ticagrelor or a 
comparator drug with no prior use of the corresponding drug in the past 6 months (washout period).  
 
Comparator agents: 
• Initiators of ticagrelor 90mg will be compared to initiators of- 
o Clopidogrel 75mg 
 
 
6.2 Preliminary covariates: 
• Age 
• Sex 
• Combined Comorbidity Index (CCI), measured over the default baseline covariate assessment period, defined as 180 days 
prior to and including index date 
 
Covariates listed above represent only a small subset of covariates that will ultimately be controlled for in the design and analysis. 
We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between 
treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the initial feasibility 
analysis and the initial power assessment and are listed in Table 1 (Appendix B). 
 
6.3 Outcome variables and study follow-up:  
 
6.3.1 Outcome variables 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
7 
Effectiveness outcomes of interest (definitions provided in Appendix A):  
• Primary outcome: 3-point major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction, non-fatal stroke, 
or CV mortality 
• Secondary outcomes: Individual components: 
o Hospital admission for MI (for purposes of this individual component, fatal MI is included) 
o Hospital admission for stroke (for purposes of this individual component, fatal stroke is included) 
o All-cause mortality/CV mortality: 
§ All-cause inpatient mortality identified using discharge status codes will be used as a proxy for “CV mortality” 
in Marketscan 
§ In Optum, all-cause inpatient mortality + all-cause mortality for Medicare Advantage patients is used 
 
Control outcome of interest (control outcomes only serve to assess aspects of study validity but are not further interpreted):  
1. Major bleeding (we expect to see a null association; Wallentin et al., 2009) 
2. Pneumonia (we expect to see a null association) 
Control outcome definition 
Outcome 
Definition 
Comments 
Control Outcomes 
Major bleeding 
Any inpatient diagnosis of major bleeding -- code list provided in Appendix A 
Same code list used for both outcome 
and major bleed exclusion criteria  
Pneumonia 
Any inpatient diagnosis of pneumonia:    
  * 481 - PNEUMOCOCCAL PNEUMONIA [STREPTOCOCCUS PNEUMONIAE PNEUMONIA] 
  * 482 - OTHER BACTERIAL PNEUMONIA 
* 483 - PNEUMONIA DUE TO OTHER SPECIFIED ORGANISM 
* 485 - BRONCHOPNEUMONIA ORGANISM UNSPECIFIED 
* 486 - PNEUMONIA ORGANISM UNSPECIFIED 
* 487.0 - INFLUENZA WITH PNEUMONIA 
* 507 - PNEUMONITIS DUE TO SOLIDS AND LIQUIDS 
* 482.0 - PNEUMONIA DUE TO KLEBSIELLA PNEUMONIAE 
* 482.1 - PNEUMONIA DUE TO PSEUDOMONAS 
* 482.2 - PNEUMONIA DUE TO HEMOPHILUS INFLUENZAE  
* 482.3 - PNEUMONIA DUE TO STREPTOCOCCUS 
* 482.30 - PNEUMONIA DUE TO STREPTOCOCCUS UNSPECIFIED 
* 482.31 - PNEUMONIA DUE TO STREPTOCOCCUS GROUP A 
* 482.32 - PNEUMONIA DUE TO STREPTOCOCCUS GROUP B 
PPV = 85% (Aronsky, et al.; 2005); 
Note- The  corresponding ICD-10 
codes will also be used 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
8 
 
6.3.2 Study follow-up 
Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on the day of 
cohort entry. Because adherence in the real-world databases is expected to be much worse than in the trial, the AT analysis is the 
primary analysis, as it targets the relative hazard of outcomes on treatment.  
 
For the AT analyses, the follow-up will start the day after initiation of ticagrelor and comparator and will continue until the earliest 
date of the following events: 
• The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,  
• The date of end of continuous registration in the database, 
• End of the study period, 
• Measured death event occurs, 
• Nursing home admission 
o Nursing home admissions are considered a censoring event because the data sources utilized typically provide little to 
no data on a patient, particularly on drug utilization, after admission. We will utilize this as an exclusion reason for 
cohorts for the same reason. 
* 482.39 - PNEUMONIA DUE TO OTHER STREPTOCOCCUS 
* 482.4 - PNEUMONIA DUE TO STAPHYLOCOCCUS 
* 482.40 - PNEUMONIA DUE TO STAPHYLOCOCCUS UNSPECIFIED 
* 482.41 - METHICILLIN SUSCEPTIBLE PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS 
* 482.42 - METHICILLIN RESISTANT PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS 
* 482.49 - OTHER STAPHYLOCOCCUS PNEUMONIA 
* 482.8 - PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA 
* 482.81 - PNEUMONIA DUE TO ANAEROBES 
* 482.82 - PNEUMONIA DUE TO ESCHERICHIA COLI [E.COLI] 
* 482.83 - PNEUMONIA DUE TO OTHER GRAM-NEGATIVE BACTERIA 
* 482.84 - PNEUMONIA DUE TO LEGIONNAIRES' DISEASE 
* 482.89 - PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA 
* 482.9 - BACTERIAL PNEUMONIA UNSPECIFIED 
* 483.0 - PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE 
* 483.1 - PNEUMONIA DUE TO CHLAMYDIA 
* 483.8 - PNEUMONIA DUE TO OTHER SPECIFIED ORGANISM 
* 507.0 - PNEUMONITIS DUE TO INHALATION OF FOOD OR VOMITUS 
* 507.1 - PNEUMONITIS DUE TO INHALATION OF OILS AND ESSENCES 
* 507.8 - PNEUMONITIS DUE TO OTHER SOLIDS AND LIQUIDS 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
9 
• The date of drug discontinuation, defined as the date of the last continuous treatment episode of the index drug (ticagrelor 
and comparator) plus a defined grace period (i.e., 30 days after the end of the last prescription’s days’ supply in main 
analyses). 
• The date of augmentation or switching from an exposure to a comparator. 
• Initiation of prasugrel 
 
For the ITT analyses, the censoring based on the augmentation/switching and treatment discontinuation will be replaced with a 
maximum allowed follow-up time of 365 days.  
 
7. Initial Feasibility Analysis  
 
Aetion report links: 
Optum: https://bwh-dope.aetion.com/projects/details/948/results/45952/result/0 
Marketscan: https://bwh-dope.aetion.com/projects/details/949/results/45949/result/0 
 
Date conducted: December 12, 2019 
 
Complete Aetion feasibility analysis using age, sex, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the 
outcome. No measures of association will be computed nor will incidence rates stratified by treatment group. 
 
• Report patient characteristics by treatment group 
• Report summary parameters of the overall study population 
• Report median follow-up time by treatment group 
• Report reasons for censoring in the overall study population 
 
8. Initial Power Assessment 
 
Aetion report links: 
Optum: https://bwh-dope.aetion.com/projects/details/948/results/45953/result/6 
Marketscan: https://bwh-dope.aetion.com/projects/details/949/results/45950/result/6 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
10 
Date conducted: December 12, 2019 
 
In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This 
outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. 
Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined 
comorbidity index. Power calculations are based on the formulas from Chow et al. (2008).  
 
In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This 
outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. 
Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined 
comorbidity index. Power calculations are based on the formulas from Chow et al. (2008). 
 
Reviewed by PI: 
Jessica Franklin 
Date reviewed: 
12/16/2019 
Reviewed by FDA: 
Ken Quinto 
Date reviewed: 
1/3/2020 
Reasons for stopping 
analysis (if required): 
 
 
 
9. Balance Assessment after PS matching 
 
Aetion report links (Ticagrelor vs. clopidogrel): 
Optum: https://bwh-dope.aetion.com/projects/details/948/results/46989/result/0 
Marketscan: https://bwh-dope.aetion.com/projects/details/949/results/46990/result/0 
 
Date conducted: 01/05/2020 
 
After review of initial feasibility and power analyses, complete creation of the remaining covariates (see Table 1 below for list of 
covariates). Again, using the dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS 
should include the complete list of covariates (excluding laboratory values, which are missing in some patients). 
 
• Provide plot of PS distributions stratified by treatment group. 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
11 
 
Note- Please refer to Appendix B.  
 
• Report covariate balance after matching. 
 
Note- For Table 1, please refer to Appendix B.  
 
• Report reasons for censoring by treatment group. 
  
Overall 
Referent 
Exposure 
Dummy Outcome 
0 (0.00%) 
0 (0.00%) 
0 (0.00%) 
Death 
194 (0.69%) 
108 (0.77%) 
86 (0.62%) 
Start of an additional exposure 
3,375 (12.07%) 
254 (1.82%) 
3,121 (22.32%) 
End of index exposure 
11,280 (40.34%) 
5,799 (41.48%) 
5,481 (39.21%) 
Specified date reached 
5,755 (20.58%) 
3,626 (25.94%) 
2,129 (15.23%) 
End of patient enrollment 
5,042 (18.03%) 
3,039 (21.74%) 
2,003 (14.33%) 
Switch to Prasugrel (for censoring) + nursing home 
admission 
2,314 (8.28%) 
1,154 (8.25%) 
1,160 (8.30%) 
 
• Report follow-up time by treatment group. 
Median Follow-Up Time (Days) [IQR] 
Patient Group 
Optum 
Marketscan 
Overall Patient Population 
163 [58-387] 
219 [85-409] 
Referent 
228 [81-444] 
259 [113-451] 
Exposure 
114 [40-310] 
179 [59-381] 
 
• Report overall risk of the primary outcome. 
  
Optum 
Marketscan 
Risk per 1,000 patients (MACE) 
75.73 
56.46 
 
10. Final Power Assessment 
 
Date conducted:  

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
12 
 
• Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. 
All other parameters in the table should be the same as in Section 8. If the study is to be implemented in more than one 
database, copy and paste excel sheet to report power for each database separately and for the pooled analysis that uses data 
from all databases together. Power calculations are based on the formulas from Chow et al. (2008). 
 
o Pooled 
§ 
For ticagrelor 90mg vs. clopidogrel 75mg (Primary outcome- MACE) 
 
 
o Optum 
§ 
For ticagrelor 90mg vs. clopidogrel 75mg (Primary outcome- MACE) 
Superiority Analysis
Number of patients matched
Reference
13,980
Exposed
13,980
Risk per 1,000 patients
66.10
Desired HR from RCT
0.865
Alpha (2-sided)
0.05
Number of events expected
1848.156
Power
0.876441293
Non-inferiority Analysis
Number of patients matched
Reference
13,980
Exposed
13,980
Risk per 1,000 patients
66.10
Assumed HR from RCT
1
Alpha (2-sided)
0.05
Non-inferiority margin
1.3
Number of events expected
1848.156
Power
0.999883191

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
13 
 
 
o MarketScan 
§ 
For ticagrelor 90mg vs. clopidogrel 75mg (Primary outcome- MACE) 
 
Superiority Analysis
Number of patients matched
Reference
6,697
Exposed
6,697
Risk per 1,000 patients
75.73
Desired HR from RCT
0.865
Alpha (2-sided)
0.05
Number of events expected
1014.32762
Power
0.636639088
Non-inferiority Analysis
Number of patients matched
Reference
6,697
Exposed
6,697
Risk per 1,000 patients
75.73
Assumed HR from RCT
1
Alpha (2-sided)
0.05
Non-inferiority margin
1.3
Number of events expected
1014.32762
Power
0.986722295
Superiority Analysis
Number of patients matched
Reference
7,283
Exposed
7,283
Risk per 1,000 patients
56.46
Desired HR from RCT
0.865
Alpha (2-sided)
0.05
Number of events expected
822.39636
Power
0.54759547
Non-inferiority Analysis
Number of patients matched
Reference
7,283
Exposed
7,283
Risk per 1,000 patients
56.46
Assumed HR from RCT
1
Alpha (2-sided)
0.05
Non-inferiority margin
1.3
Number of events expected
822.39636
Power
0.964227735

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
14 
 
• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of 
advisory board. Reviewers evaluate the results of the analyses described above in Sections 9 and 10, including numbers of 
patients, balance in patient characteristics, follow-up time, and reasons for censoring by treatment group, as well as overall rates 
of outcomes and study power. 
Reviewed by PI: 
Jessica Franklin 
Date reviewed: 
12/16/2019 
Reviewed by FDA: 
Ken Quinto 
Date reviewed: 
01/03/2020 
Reasons for stopping 
analysis (if required): 
 
 
11. Study Confidence and Concerns 
 
Deadline for voting on study confidence and listing concerns: 1/10/20 
 
• If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps. 
• All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the 
success of the RWD study in the Google Form. This form also provides space for reviewers to list any concerns that they feel may 
contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study 
variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the 
individual respondent. 
 
12. Register study protocol on clinicalTrials.gov 
 
Date conducted:    
 
• Register the study on clinicalTrials.gov and upload this document. 
 
13. Comparative Analyses 
 
Aetion report name: 
Date conducted:    

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
15 
 
13.1 
For primary analysis:  
 
• In the PS-matched cohort from Section 9, calculate the HR for each outcome for ticagrelor versus clopidogrel patients using a Cox 
proportional hazards model.  
 
13.2 
For secondary analyses: 
• In both pre-matched cohorts, perform asymmetrical trimming to remove patients with PS values below the 2.5th percentile of 
treated patients and above the 97.5th percentile of untreated patients. In the trimmed cohort, calculate the HR for ticagrelor 
versus referent patients using a Cox proportional hazards model, adjusting for deciles of the PS. 
 
 
14.  Requested Results  
 
14.1 
Results from primary and secondary analyses; 
 
Analysis 
No. exposed events 
No. referent events 
Exposed rate 
Referent rate 
HR (95% CI) 
Crude 
 
 
 
 
 
Primary analysis 
 
 
 
 
 
Analysis 2 
 
 
 
 
 
... 
 
 
 
 
 
HR, Hazard Ratio; CI, Confidence Interval. 
 
15. References 
 
 
Aronsky, Dominik, et al. Accuracy of Administrative Data for Identifying Patients with Pneumonia. American Journal of Medical 
Quality. 2005: 20(6);319–28. doi:10.1177/1062860605280358. 
 
Chow S, Shao J, Wang H. 2008.  Sample Size Calculations in Clinical Research. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 
177 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
16 
 
Wallentin L, Becker RC, Budaj A, et al. N Engl J Med 2009; 361:1045-1057 

# 
PLATO trial definitions 
Implementation in routine care
References/Rationale
Color coding
Please see the following Google Drive for further details or any missing information: 
https://drive.google.com/open?id=1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV
Adequate mapping in claims
Not all ICD-10 codes are not listed in this document because of excel cell size limitations and excessive 
number of ICD-10 codes. Full ICD-10 code lists will be available in the above Google Drive Folder (link 
above). ICD-9 to ICD-10 code conversions were completed using a SAS macro that implements forward/ 
backward mapping based on the CMS ICD-9 to ICD-10 mapping: https://www.nber.org/data/icd9-icd-10-
cm-and-pcs-crosswalk-general-equivalence-mapping.html
Intermediate mapping in claims
Ticagrelor  (90 mg twice daily)  vs Clopidogrel  (75mg daily)
Exposure) Ticagrelor 
Reference) Clopidogrel 
KEY TIME POINTS: 
Index event : Onset of Acute coronary syndrome (ACS) which becomes the indication for study 
drug (ticagrelor or clopidogrel) initiation 
Index hospitalization: Hospitalization for the treatment of index event 
Drug initiation date: New prescription claim for the study drug in patients with a record of 
index hospitalization in the previous 2 weeks.
* We assume that the patient first initates study drug in hospital and continues to be part of 
the initiator group as long as a prescription is filled within 2 weeks of discharge of ACS event. 
Poor mapping or cannot be measured in 
claims 
Can't be measured in claims but not 
important for the analysis
The primary efficacy end point is time to first occurrence of death from vascular causes, myocardial infarction, 
or stroke.
Measured 1 day after drug initiation in diagnosis position specified below and inpatient care setting:
Inpatient mortality/MI/Stroke 
For MI
Any diagnosis position in inpatient care setting
ICD-9 Dx 410.X (acute myocardial infarction) excluding 410.x2 (subsequent episode of care)
For stroke
Primary diagnosis position in inpatient care setting 
ICD-9 discharge diagnosis:
430.xx  Subarachnoid hemorrhage (SAH)
431.xx  Intracerebral hemorrhage (ICH)
433.x1  Occlusion and stenosis of precerebral arteries with cerebral infarction
434.xx (excluding 434.x0)  Occlusion and stenosis of cerebral arteries with cerebral infarction
436.x  Acute, but ill-defined cerebrovascular events
Mortality- See Mortality Sheet.
For MI: 
PPV 94% in Medicare claims data [Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn 
J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: 
estimating positive predictive value on the basis of review of hospital records. American heart 
journal 2004;148:99-104.]
PPV 88.4% in commercially-insured population [Wahl PM, Rodgers K, Schneeweiss S, et al. 
Validation of claims-based diagnostic and procedure codes for cardiovascular and 
gastrointestinal serious adverse events in a commercially-insured population. 
Pharmacoepidemiology and Drug Safety 2010;19:596-603.]
For stroke:
PPV of 85% or higher for ischemic stroke
PPV ranging from 80% to 98% for hemorrhagic stroke
[Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for 
identifying cerebrovascular accident or transient ischemic attack using administrative data. 
Pharmacoepidemiology and Drug Safety 2012;21 Suppl 1:100-28.]
[Tirschwell DL, Longstreth WT, Jr. Validating administrative data in stroke research. Stroke; 
a journal of cerebral circulation 2002;33:2465-70.]
[Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation 
of ICD-9 codes with a high positive predictive value for incident strokes resulting in 
hospitalization using Medicaid health data. Pharmacoepidemiology and drug safety 
2008;17:20-6.]
1
Hospitalized for potential ST-segment elevation or non–ST-segment elevation ACS, with onset during the 
previous 24 hours, documented by cardiac ischemic symptoms due to atherosclerosis of ≥10 minutes' 
duration at rest
Measured 2 weeks prior to index hospitalization in inpatient, primary diagnosis position
Acute MI: 
ICD-9 Dx 410.X (acute myocardial infarction) excluding 410.x2 (subsequent episode of care)
ICD-10: 
I21.0x, I21.1x, I21.2x, I21.3x, I21.4x, I22.0x, I22.0x, I22.1x, I22.2x, I22.8x, I22.9x, I25.2x
Unstable angina: 
ICD-9: 411.x
ICD-10: I24.1x, I20.0x, I25.1x, I25.7x, I24.0x, I24.8x, I24.9x 
2
≥18 years of age
Measured at index hospitalization 
Age >=18
3
Not pregnant. 
Urinary and/or blood pregnancy tests are to be performed in women of child-bearing potential and repeated at 
least every 6 months. Women of child-bearing potential must be using ≥2 forms of reliable contraception, 
including one barrier method. 
Please see exclusion #13
4
With informed consent
N/A
5A
≥2 of the following 3 risk factors 
* Note) In the claims, we are unable to measure ≥2 of the 3 risk factors 
1. ST-segment changes on ECG indicating ischemia. 
ST-segment depression or transient elevation ≥ 1 mm in two or more 2 contiguous leads
N/A
PRIMARY OUTCOME
Trial details-  Hazard Ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92 )
EXPOSURE vs. COMPARISON
INCLUSION CRITERIA
1-4 ALL FOUR ARE REQUIRED
IN ADDITION TO 1-4, MEET CRITERIA 5A OR 5B
Appendix A

2. Positive biomarker indicating myocardial necrosis. Troponin I or T or CK-MB greater than the upper limit of 
normal
N/A
3. One of the following:
(a) ≥60 y of age
Measured at index hospitalization 
Age >= 60
 (b) Previous MI or CABG 
Measured any time prior to index hospitalization in any diagnosis position and inpatient or outpatient care setting as 
defined below:
MI: 
ICD-9 Acute MI: 410.xx, Old MI: 412.xx
CABG:
Inpatient CPT-4: 33510 – 33536, 33545, 33572. 
Or
Inpatient or outpatient ICD-9 procedure: 36.1x, 36.2x
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other 
non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 
http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in 
Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and 
Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
(c) CAD with ≥50% stenosis in ≥2 vessels
N/A
(d) Previous ischemic stroke, TIA (hospital-based diagnosis), carotid stenosis (≥50%), or cerebral 
revascularization
Measured any time prior to index hospitalization in any diagnosis position and inpatient or outpatient care setting as 
defined below:
(exception: TIA - inpatient diagnosis only) 
Ischemic stroke: 
ICD-9: 433.x, 434. x 
TIA (inpatient diagnosis, any position) : 
ICD-9 : 435.xx  
Carotid stenosis: 
ICD-9: 433.1x
Cerebral revascularization: 
ICD-9 procedure code
Carotid endarterectomy (38.12), 
Angioplasty/atherectomy of precerebral vessels (00.61)
Carotid artery stenting (00.63).
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other 
non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 
http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in 
Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and 
Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
(e) Diabetes mellitus
Measured 365 days prior to drug initiation in any diagnosis position and inpatient or outpatient care setting as defined 
below:
Diabetes type 1: 
ICD-9 : 250.x1 or 250.x
ICD-10:  E10.x 
Diabetes type 2: 
ICD-9: 250.x0 or 250.x2
ICD-10 E11.x
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other 
non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 
http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in 
Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and 
Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
(f) Peripheral artery disease 
Measured 365 days prior drug initiation in any diagnosis position and inpatient or outpatient care setting as defined 
below:
Peripheral vascular disease
ICD-9: 
440.20 – 440.24, 440.29 – 440.32,  440.3, 440.4, 443.9  
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other 
non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 
http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in 
Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and 
Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
 (g) Chronic renal dysfunction
Measured 365 days prior to drug initiation in any diagnosis position and inpatient or outpatient care setting as defined 
below:
Chronic kidney disease: 
ICD-9: 
585.3x-585.6x
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other 
non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 
http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in 
Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and 
Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
OR 
5B
Persistent ST-segment elevation ≥1 mm (not known to be preexisting or due to a coexisting disorder) in ≥2 
contiguous leads or new LBBB plus primary PCI planned.
N/A
EXCLUSION CRITERIA
Drug related
Appendix A

1
1. Contraindication to clopidogrel or other reason that study drug should not be administered (eg, 
hypersensitivity, moderate or severe liver disease, active bleeding or bleeding history, 
major surgery within 30 days)
Moderate/severe liver disease: 
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient care  setting 
ICD-9 diagnosis codes: 
070.xx, 570.xx- 573.xx 
456.0x-456.2x, 576.8x, 782.4x, 789.5x 
ICD-9 procedure codes:
39.1x, 42.91 
Active bleeding or bleeding history: 
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient care  setting 
Codes are in the sheet 'Major Bleeding'
Majory surgery (except cardiac surgeries):
Measured 30 days prior to drug initiation in any diagnosis position and inpatient or outpatient care  setting 
Major surgery selected from ICD-9 procedure codes range 40.x- 84.x 
(procedures 35.x -39.x [cardiovascular procedures] are excluded)
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other 
non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 
http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in 
Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and 
Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
2
2. Oral anticoagulation therapy that cannot be stopped
N/A
3
3. Fibrinolytic therapy planned or within the previous 24 h
N/A
4
4. Concomitant oral or IV therapy with strong CYP3A
inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, 
saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic 
indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin/rifampicin, phenytoin, carbamazepine)
Prescription claim for following CYP3A inhibitors, CYP3A substrates, or strong CYP3A inducers
Measured 90 days prior to drug initiation
Ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, 
indinavir, atazanavir
Cyclosporine, quinidine
Rifampin, rifampicin/rifampin, phenytoin, carbamazepine
5
1. Index event is an acute complication of PCI
N/A
6
2. PCI after index event and before first study dose
N/A
7
1. Increased risk of bradycardiac events
N/A
8
2. Dialysis required
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient care setting
Codes are in the sheet 'Dialysis'
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other 
non-gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 
http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in 
Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and 
Safety (EMPRISE) Study." Circulation. 2019 Apr 8. doi:
9
3. Known clinically important thrombocytopenia
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient care  setting 
Thrombocytopenia
ICD-9: 287.3x, 287.4x, 287.5x
10
4. Known clinically important anemia
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient care  setting 
Anemia (unspecified anemia including anemia of chronic illness, sideroblastic anemia) 
ICD-9: 285.x 
11
5. Any other condition that may put the patient at risk or influence study results in the investigators' opinion
(eg, cardiogenic shock, severe hemodynamic instability, active cancer)
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient care  setting 
Cardiogenic shock: 
ICD-9: 785.51
Severe hemodynamic instability: 
ICD-9: 
785.59 Other shock without mention of trauma
785.52  Septic shock
785.50 shock, unspecified
Active cancer: 
ICD-9: 
History of malignant neoplasm 140.xx-208.xx (except 173.xx, non-melanoma skin cancer)
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin versus other non-
gliflozin antidiabetic drugs: population based cohort study." BMJ 2018;360:k119 
http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical 
Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study."  
Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177
12
1. Participant in another investigational drug or device study within 30 days
N/A
Treatment Related
General
Medical Related
Appendix A

13
2. Pregnancy or lactation
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or outpatient care setting 
Codes are in the sheet "Pregnancy"
14
3. Any condition that increases the risk for noncompliance or being lost to follow-up
N/A
15
4. Involvement in the planning or conduct of the study
N/A
16
5. Previous enrollment or randomization in this study
N/A
Appendix A

Trial ID 
pNDA10
Trial Name (with web links) 
PLATO
Trial Name (with pdf links)
PLATO
NCT 
NCT00391872 
Trial category
Primary indication
Run-in period Description
Run-in period
Therapeutic Area
Cardiology/Vascular Diseases
Study batch
Antiplatelets
RCT Category  
1a- Intended S with label change
Brand Name
Brilinta 
Generic Name
ticagrelor
Sponsor
 AstraZeneca
Year
2011
Measurable endpoint
Primary composite endpoint of 
cardiovascular death, non-fatal MI 
(excluding silent MI), or non-fatal 
stroke
Exposure
Ticagrelor
Comparator
Clopidogrel
Population
Patients admitted to the hospital with 
an acute coronary syndrome, with or 
without ST-segment elevation. 89% 
patients on Beta-blocker, 76% ACE 
inhibitors, 89% on statins
Trial finding
RR = 0.84 (95% CI 0.77–0.92)
Notes
 No. of Patients 
                                                    18,624 
Non-inferiority margin
-
Assay Sens. Outcome
Assay Sens. Endpoint (from trial)
Appendix A

Finding for potential Assay Sens. Outcome 
from trial- 
Power
0.90 to detect a relative risk reduction 
of 13.5% in the rate of the primary end 
point 
Blinding
Double-blinded
Statistical Method
Approval indication
 For the reduction of thrombotic events 
in patients with acute coronary 
syndrome
Appendix A

Mortality- Dependent on data source. 
1. All-cause mortality / inpatient mortality
Identified using the vital status file-
Medicare
Identified using the discharge status codes-
Optum-
• 20 = EXPIRED
• 21 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 22 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 23 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 24 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 25 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 26 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 27 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 28 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 29 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 40 = EXPIRED AT HOME (HOSPICE)
• 41 = EXPIRED IN A MEDICAL FACILITY (HOSPICE)
• 42 = EXPIRED - PLACE UNKNOWN (HOSPICE)
Truven-
• 20 - Died
• 22 - Died
• 23 - Died
• 24 - Died
• 25 - Died
• 26 - Died
• 27 - Died
• 28 - Died
• 29 - Died
• 40 - Other died status or Expired at home (Hospice claims only) (depends on year)
• 41 - Other died status or Expired in medical facility (Hospice claims only) (depends on year)
Appendix A

• 42 - Other died status or Expired - place unknown (Hospice claims only) (depends on year)
• 21 - Died or Disch./Transf. to court/law enforcement (depends on year)
2. CV mortality
Information on CV mortality through data linkage with the National Death Index (NDI) will be available for Medicare 
at a later date. We will conduct secondary analyses using CV mortality at that time.
Appendix A

Major bleeding control outcome: 1 inpatient (any position)
Major bleeding exclusion criteria: 1 inpatient (any position) or 2 outpatient diagnosis (separated by 7-365 days)
562.02
 (ICD9) DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
562.03
 (ICD9) DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.12
 (ICD9) DIVERTICULOSIS OF COLON WITH HEMORRHAGE
562.13
 (ICD9) DIVERTICULITIS OF COLON WITH HEMORRHAGE
568.81
 (ICD9) HEMOPERITONEUM (NONTRAUMATIC)
569.3
 (ICD9) HEMORRHAGE OF RECTUM AND ANUS
569.83
 (ICD9) PERFORATION OF INTESTINE
569.85
 (ICD9) ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
569.86
 (ICD9) DIEULAFOY LESION (HEMORRHAGIC) OF INTESTINE
578
 (ICD9) HEMATEMESIS
578.9
 (ICD9) HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
423
 (ICD9) HEMOPERICARDIUM
432
 (ICD9) NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1
 (ICD9) SUBDURAL HEMORRHAGE
432.9
 (ICD9) UNSPECIFIED INTRACRANIAL HEMORRHAGE
459
 (ICD9) HEMORRHAGE UNSPECIFIED
531
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE
531
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.01
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.2
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.2
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.21
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE
531.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.41
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.61
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE
532
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.01
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.2
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
Appendix A

532.2
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.21
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.4
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
532.4
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.41
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.6
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.6
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.61
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.01
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.2
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.2
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.21
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.4
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533.4
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.41
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.6
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.6
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.61
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.01
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.2
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.2
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.21
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.41
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.61
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
578.1
 (ICD9) BLOOD IN STOOL
719.1
 (ICD9) HEMARTHROSIS
719.1
 (ICD9) HEMARTHROSIS SITE UNSPECIFIED
Appendix A

719.11
 (ICD9) HERARTHROSIS INVOLVING SHOULDER REGION
719.12
 (ICD9) HEMARTHORSIS INVOLVING UPPER ARM
719.13
 (ICD9) HEMARTHROSIS INVOLVING FOREARM
719.14
 (ICD9) HEMARTHROSIS INVOLVING HAND
719.15
 (ICD9) HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
719.16
 (ICD9) HEMARTHROSIS INVOLVING LOWER LEG
719.17
 (ICD9) HEMARTHROSIS INVOLVING ANKLE AND FOOT
719.18
 (ICD9) HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES
719.19
 (ICD9) HEMARTHROSIS INVOLVING MULTIPLE SITES
430
 (ICD9) SUBARACHNOID HEMORRHAGE
431
 (ICD9) INTRACEREBRAL HEMORRHAGE
I31.2 
 (ICD10) Hemopericardium, not elsewhere classified
I60.00 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
I60.01 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.02 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.10 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
I60.11 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.12 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
I60.2 
 (ICD10) Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.30 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
I60.31 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.32 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.4 
 (ICD10) Nontraumatic subarachnoid hemorrhage from basilar artery
I60.50 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
I60.51 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.52 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6 
 (ICD10) Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.7 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
I60.8 
 (ICD10) Other nontraumatic subarachnoid hemorrhage
I60.9 
 (ICD10) Nontraumatic subarachnoid hemorrhage, unspecified
I61.0 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.1 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, cortical
I61.2 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
I61.3 
 (ICD10) Nontraumatic intracerebral hemorrhage in brain stem
I61.4 
 (ICD10) Nontraumatic intracerebral hemorrhage in cerebellum
Appendix A

I61.5 
 (ICD10) Nontraumatic intracerebral hemorrhage, intraventricular
I61.6 
 (ICD10) Nontraumatic intracerebral hemorrhage, multiple localized
I61.8 
 (ICD10) Other nontraumatic intracerebral hemorrhage
I61.9 
 (ICD10) Nontraumatic intracerebral hemorrhage, unspecified
I62.00 
 (ICD10) Nontraumatic subdural hemorrhage, unspecified
I62.01 
 (ICD10) Nontraumatic acute subdural hemorrhage
I62.02 
 (ICD10) Nontraumatic subacute subdural hemorrhage
I62.03 
 (ICD10) Nontraumatic chronic subdural hemorrhage
I62.1 
 (ICD10) Nontraumatic extradural hemorrhage
I62.9 
 (ICD10) Nontraumatic intracranial hemorrhage, unspecified
K25.0 
 (ICD10) Acute gastric ulcer with hemorrhage
K25.2 
 (ICD10) Acute gastric ulcer with both hemorrhage and perforation
K25.4 
 (ICD10) Chronic or unspecified gastric ulcer with hemorrhage
K25.6 
 (ICD10) Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0 
 (ICD10) Acute duodenal ulcer with hemorrhage
K26.2 
 (ICD10) Acute duodenal ulcer with both hemorrhage and perforation
K26.4 
 (ICD10) Chronic or unspecified duodenal ulcer with hemorrhage
K26.6 
 (ICD10) Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.0 
 (ICD10) Acute peptic ulcer, site unspecified, with hemorrhage
K27.2 
 (ICD10) Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K27.4 
 (ICD10) Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.6 
 (ICD10) Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0 
 (ICD10) Acute gastrojejunal ulcer with hemorrhage
K28.2 
 (ICD10) Acute gastrojejunal ulcer with both hemorrhage and perforation
K28.4 
 (ICD10) Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.6 
 (ICD10) Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K55.21 
 (ICD10) Angiodysplasia of colon with hemorrhage
K56.60 
 (ICD10) Unspecified intestinal obstruction
K57.01 
 (ICD10) Diverticulitis of small intestine with perforation and abscess with bleeding
K57.11 
 (ICD10) Diverticulosis of small intestine without perforation or abscess with bleeding
K57.13 
 (ICD10) Diverticulitis of small intestine without perforation or abscess with bleeding
K57.21 
 (ICD10) Diverticulitis of large intestine with perforation and abscess with bleeding
K57.31 
 (ICD10) Diverticulosis of large intestine without perforation or abscess with bleeding
K57.33 
 (ICD10) Diverticulitis of large intestine without perforation or abscess with bleeding
K57.41 
 (ICD10) Diverticulitis of both small and large intestine with perforation and abscess with bleeding
Appendix A

K57.51 
 (ICD10) Diverticulosis of both small and large intestine without perforation or abscess with bleeding
K57.53 
 (ICD10) Diverticulitis of both small and large intestine without perforation or abscess with bleeding
K57.81 
 (ICD10) Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91 
 (ICD10) Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K57.93 
 (ICD10) Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
K62.5 
 (ICD10) Hemorrhage of anus and rectum
K63.1 
 (ICD10) Perforation of intestine (nontraumatic)
K63.81 
 (ICD10) Dieulafoy lesion of intestine
K66.1 
 (ICD10) Hemoperitoneum
K92.0 
 (ICD10) Hematemesis
K92.1 
 (ICD10) Melena
K92.2 
 (ICD10) Gastrointestinal hemorrhage, unspecified
M25.00 
 (ICD10) Hemarthrosis, unspecified joint
M25.011 
 (ICD10) Hemarthrosis, right shoulder
M25.012 
 (ICD10) Hemarthrosis, left shoulder
M25.019 
 (ICD10) Hemarthrosis, unspecified shoulder
M25.021 
 (ICD10) Hemarthrosis, right elbow
M25.022 
 (ICD10) Hemarthrosis, left elbow
M25.029 
 (ICD10) Hemarthrosis, unspecified elbow
M25.031 
 (ICD10) Hemarthrosis, right wrist
M25.032 
 (ICD10) Hemarthrosis, left wrist
M25.039 
 (ICD10) Hemarthrosis, unspecified wrist
M25.041 
 (ICD10) Hemarthrosis, right hand
M25.042 
 (ICD10) Hemarthrosis, left hand
M25.049 
 (ICD10) Hemarthrosis, unspecified hand
M25.051 
 (ICD10) Hemarthrosis, right hip
M25.052 
 (ICD10) Hemarthrosis, left hip
M25.059 
 (ICD10) Hemarthrosis, unspecified hip
M25.061 
 (ICD10) Hemarthrosis, right knee
M25.062 
 (ICD10) Hemarthrosis, left knee
M25.069 
 (ICD10) Hemarthrosis, unspecified knee
M25.071 
 (ICD10) Hemarthrosis, right ankle
M25.072 
 (ICD10) Hemarthrosis, left ankle
M25.073 
 (ICD10) Hemarthrosis, unspecified ankle
M25.074 
 (ICD10) Hemarthrosis, right foot
Appendix A

M25.075 
 (ICD10) Hemarthrosis, left foot
M25.076 
 (ICD10) Hemarthrosis, unspecified foot
M25.08 
 (ICD10) Hemarthrosis, other specified site
R58 
 (ICD10) Hemorrhage, not elsewhere classified
R04 
 (ICD10) Hemorrhage from respiratory passages
R04.0 
 (ICD10) Epistaxis
R04.1 
 (ICD10) Hemorrhage from throat
R04.2 
 (ICD10) Hemoptysis
R04.8 
 (ICD10) Hemorrhage from other sites in respiratory passages
R04.81 
 (ICD10) Acute idiopathic pulmonary hemorrhage in infants
R04.89 
 (ICD10) Hemorrhage from other sites in respiratory passages
R04.9 
 (ICD10) Hemorrhage from respiratory passages, unspecified
R31 
 (ICD10) Hematuria
R31.0 
 (ICD10) Gross hematuria
R31.1 
 (ICD10) Benign essential microscopic hematuria
R31.2 
 (ICD10) Other microscopic hematuria
R31.21
R31.29
R31.9 
 (ICD10) Hematuria, unspecified
784.7
 (ICD9) EPISTAXIS
784.8
 (ICD9) HEMORRHAGE FROM THROAT
599.7
 (ICD9) HEMATURIA
599.7
 (ICD9) HEMATURIA UNSPECIFIED
599.71
 (ICD9) GROSS HEMATURIA
599.72
 (ICD9) MICROSCOPIC HEMATURIA
786.3
 (ICD9) HEMOPTYSIS
786.3
 (ICD9) HEMOPTYSIS UNSPECIFIED
786.31
 (ICD9) ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS
786.39
 (ICD9) OTHER HEMOPTYSIS
The occurrence of Inpatient with the following attributes:
 Procedure Code (Any Position) is any of: { “44.43”, “43255”, “0W3P8ZZ” }
44.43
 (ICD9) ENDOSCOPIC CONTROL OF GASTRIC OR DUODENAL BLEEDING
43255
 (HCPCS) Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method / Upper gastrointestinal endoscopy 
including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with control of bleeding, any method
0W3P8ZZ 
 (ICD10) Control Bleeding in Gastrointestinal Tract, Via Natural or Artificial Opening Endoscopic
Appendix A

Dialysis codes
ESRD, defined as 2 codes (either inpatient or outpatient), separated by at least 30 days 
Codes include:
- ICD9 prox codes: 
39.95, Hemodialysis
54.98, Peritoneal dialysis
- ICD9 dx codes: 
585.5x, Chronic kidney disease, Stage V (for ESRD with no mention of dialysis) 
585.6x, End stage renal disease (for ESRD with dialysis) 
V56.0x, encounter for dialysis NOS
V56.8x, encounter for peritoneal dialysis
V45.1x, renal dialysis status
- CPT4 codes: 
90957, 90960, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 4 or more face-to-face physician 
visits per month
90958, 90961, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 2-3 face-to-face physician visits per 
month
90959, 90962, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 1 face-to-face physician visit per 
month
90920, 90921, ESRD related services per full month; for patients 12-19 and twenty years of age and over
90924, 90925, ESRD related services (less than full month), per day; for patients 12-19 and twenty years of age and over
90935, Hemodialysis procedure with single physician evaluation
90937, Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription
90945, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement 
therapies), with single physician evaluation
90947, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement 
therapies) requiring repeated physician evaluations, with or without substantial revision of dialysis prescription
90965, 90966, ESRD related services for home dialysis per full month, for patients 12-19 and 20 years of age and older
90969, 90970, ESRD related services for dialysis less than a full month of service, per day; for patients 12-19 and 20 years of age and 
older
90989, Dialysis training, patient, including helper where applicable, any mode, completed course
90993, Dialysis training, patient, including helper where applicable, any mode, course not completed, per training session
90999, Unlisted dialysis procedure, inpatient or outpatient
99512, Home visit for hemodialysis
- HCPCS codes:
G0257, Unscheduled or emergency dialysis treatment for ESRD patient in a hospital outpatient dept. that is not certified as an ESRD 
facility 
G0314, G0317, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age an over to include monitoring 
for the adequacy of nutrition, etc. w/4 or more physician visit per month
G0315, G0318, ESRD related services during the course of treatment, for patients 12-19 and 20yrs of age and over to include monitoring 
for the adequacy of nutrition etc w/2 or 3 physician visit per month
Appendix A

for the adequacy of nutrition, etc. w/2 or 3 physician visit per month
G0316, G0319, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age and over to include monitoring 
for the adequacy of nutrition, etc. w/1 physician visit per month
Appendix A

Pregnancy 
Dx codes 
650   NORMAL DELIVERY
660   OBSTRUCTED LABOR
661   ABNORMALITY OF FORCES OF LABOR
662   LONG LABOR
663   UMBILICAL CORD COMPLICATIONS DURING LABOR AND DELIVERY
664   TRAUMA TO PERINEUM AND VULVA DURING DELIVERY
665   OTHER OBSTETRICAL TRAUMA
667   RETAINED PLACENTA OR MEMBRANES WITHOUT HEMORRHAGE
668   COMPLICATIONS OF THE ADMINISTRATION OF ANESTHETIC OR OTHER SEDATION IN LABOR AND DELIVERY
669.94   UNSPECIFIED COMPLICATION OF LABOR AND DELIVERY POSTPARTUM CONDITION OR COMPLICATION
V24   POSTPARTUM CARE AND EXAMINATION
V24.0   POSTPARTUM CARE AND EXAMINATION IMMEDIATELY AFTER DELIVERY
V24.1   POSTPARTUM CARE AND EXAMINATION OF LACTATING MOTHER
V24.2   ROUTINE POSTPARTUM FOLLOW
V27   OUTCOME OF DELIVERY
V27.0   MOTHER WITH SINGLE LIVEBORN
V27.1   MOTHER WITH SINGLE STILLBORN
V27.2   MOTHER WITH TWINS BOTH LIVEBORN
V27.3   MOTHER WITH TWINS ONE LIVEBORN AND ONE STILLBORN
V27.4   MOTHER WITH TWINS BOTH STILLBORN
V27.5   MOTHER WITH OTHER MULTIPLE BIRTH ALL LIVEBORN
V27.6   MOTHER WITH OTHER MULTIPLE BIRTH SOME LIVEBORN
V27.7   MOTHER WITH OTHER MULTIPLE BIRTH ALL STILLBORN
V27.9   MOTHER WITH UNSPECIFIED OUTCOME OF DELIVERY
Procedure codes 
72.0   LOW FORCEPS OPERATION
72.1   LOW FORCEPS OPERATION WITH EPISIOTOMY
72.2   MID FORCEPS OPERATION
72.21   MID FORCEPS OPERATION WITH EPISIOTOMY
72.29   OTHER MID FORCEPS OPERATION
72.3   HIGH FORCEPS OPERATION
72.31   HIGH FORCEPS OPERATION WITH EPISIOTOMY
72.39   OTHER HIGH FORCEPS OPERATION
Appendix A

72.4   FORCEPS ROTATION OF FETAL HEAD
72.5   BREECH EXTRACTION
72.51   PARTIAL BREECH EXTRACTION WITH FORCEPS TO AFTERCOMING HEAD
72.52   OTHER PARTIAL BREECH EXTRACTION
72.53   TOTAL BREECH EXTRACTION WITH FORCEPS TO AFTERCOMING HEAD
72.54   OTHER TOTAL BREECH EXTRACTION
72.6   FORCEPS APPLICATION TO AFTERCOMING HEAD
72.7   VACUUM EXTRACTION
72.71   VACUUM EXTRACTION WITH EPISIOTOMY
72.79   OTHER VACUUM EXTRACTION
72.8   OTHER SPECIFIED INSTRUMENTAL DELIVERY
72.9   UNSPECIFIED INSTRUMENTAL DELIVERY
73.0   ARTIFICIAL RUPTURE OF MEMBRANES
73.01   INDUCTION OF LABOR BY ARTIFICIAL RUPTURE OF MEMBRANES
73.09   OTHER ARTIFICIAL RUPTURE OF MEMBRANES
73.1   OTHER SURGICAL INDUCTION OF LABOR
73.2   INTERNAL AND COMBINED VERSION AND EXTRACTION
73.21   INTERNAL AND COMBINED VERSION WITHOUT EXTRACTION
73.22   INTERNAL AND COMBINED VERSION WITH EXTRACTION
73.3   FAILED FORCEPS
73.4   MEDICAL INDUCTION OF LABOR
73.5   MANUALLY ASSISTED DELIVERY
73.51   MANUAL ROTATION OF FETAL HEAD
73.59   OTHER MANUALLY ASSISTED DELIVERY
73.6   EPISIOTOMY
73.8   OPERATIONS ON FETUS TO FACILITATE DELIVERY
73.9   OTHER OPERATIONS ASSISTING DELIVERY
73.91   EXTERNAL VERSION ASSISTING DELIVERY
73.92   REPLACEMENT OF PROLAPSED UMBILICAL CORD
73.93   INCISION OF CERVIX TO ASSIST DELIVERY
73.94   PUBIOTOMY TO ASSIST DELIVERY
73.99   OTHER OPERATIONS ASSISTING DELIVERY
74.0   CLASSICAL CESAREAN SECTION
74.1   LOW CERVICAL CESAREAN SECTION
74.2   EXTRAPERITONEAL CESAREAN SECTION
Appendix A

74.3   REMOVAL OF EXTRATUBAL ECTOPIC PREGNANCY
74.4   CESAREAN SECTION OF OTHER SPECIFIED TYPE
74.9   CESAREAN SECTION OF UNSPECIFIED TYPE
74.91   HYSTEROTOMY TO TERMINATE PREGNANCY
74.99   OTHER CESAREAN SECTION OF UNSPECIFIED TYPE
75.4   MANUAL REMOVAL OF RETAINED PLACENTA
75.5   REPAIR OF CURRENT OBSTETRIC LACERATION OF UTERUS
75.6   REPAIR OF OTHER CURRENT OBSTETRIC LACERATION
75.7   MANUAL EXPLORATION OF UTERINE CAVITY, POSTPARTUM
75.9   OTHER OBSTETRIC OPERATIONS
Appendix A

AFTER PS MATCHING
Optum
MarketScan
BEFORE PS MATCHING
The c-statistics for the propensity score model, pre-matching was 0.744. The post-matching c-statistic 
was 0.538.
The c-statistics for the propensity score model, pre-matching was 0.722. The post-matching 
c-statistic was 0.528.
Appendix B

Variable
Clopidogrel 75mg
Ticagrelor 90mg
St. Diff.
Clopidogrel 75mg
Ticagrelor 90mg
St. Diff.
Clopidogrel 75mg
Ticagrelor 90mg
St. Diff.
Number of patients
                                  34,251                                      7,078 
                                32,565                                    8,264 
                              66,816                               15,342 
Age
...mean (sd)
70.43 (10.74)
67.99 (10.81)
0.23
66.08 (12.03)
62.10 (10.28)
0.36
68.31 (11.39)
64.82 (10.53)
0.32
...median [IQR]
71.00 [64.00, 79.00]
69.00 [61.00, 76.00]
0.19
64.00 [59.00, 74.00]
62.00 [56.00, 67.00]
0.18
67.59 (11.39)
65.23 (10.53)
0.22
Age categories
...18 - 54; n (%)
2,810 (8.2%)
821 (11.6%)
-0.11
4,940 (15.2%)
1,688 (20.4%)
-0.14
7,750 (11.6%)
2,509 (16.4%)
-0.14
...55 - 64; n (%)
6,438 (18.8%)
1,599 (22.6%)
-0.09
12,321 (37.8%)
4,014 (48.6%)
-0.22
18,759 (28.1%)
5,613 (36.6%)
-0.18
...65 - 74; n (%)
12,095 (35.3%)
2,625 (37.1%)
-0.04
7,185 (22.1%)
1,526 (18.5%)
0.09
19,280 (28.9%)
4,151 (27.1%)
0.04
...>= 75; n (%)
12,908 (37.7%)
2,033 (28.7%)
0.19
8,119 (24.9%)
1,036 (12.5%)
0.32
21,027 (31.5%)
3,069 (20.0%)
0.27
Gender
...Males; n (%)
21,162 (61.8%)
4,536 (64.1%)
-0.05
21,484 (66.0%)
5,919 (71.6%)
-0.12
42,646 (63.8%)
10,455 (68.1%)
-0.09
...Females; n (%)
13,089 (38.2%)
2,542 (35.9%)
0.05
11,081 (34.0%)
2,345 (28.4%)
0.12
24,170 (36.2%)
4,887 (31.9%)
0.09
Region
...Northeast; n (%)
4,152 (12.1%)
804 (11.4%)
0.02
6,331 (19.4%)
1,562 (18.9%)
0.01
10,483 (15.7%)
2,366 (15.4%)
0.01
...South; n (%)
14,216 (41.5%)
3,335 (47.1%)
-0.11
9,450 (29.0%)
2,199 (26.6%)
0.05
23,666 (35.4%)
5,534 (36.1%)
-0.01
...Midwest; n (%)
8,706 (25.4%)
1,626 (23.0%)
0.06
11,688 (35.9%)
3,597 (43.5%)
-0.16
20,394 (30.5%)
5,223 (34.0%)
-0.07
...West; n (%)
7,177 (21.0%)
1,313 (18.6%)
0.06
4,769 (14.6%)
868 (10.5%)
0.12
11,946 (17.9%)
2,181 (14.2%)
0.10
...Unknown+missing; n (%)
N/A
N/A
#VALUE!
327 (1.0%)
38 (0.5%)
0.06
327 (0.5%)
38 (0.2%)
0.05
CV Covariates
Ischemic heart disease; n (%)
34,251 (100.0%)
7,078 (100.0%)
#DIV/0!
32,565 (100.0%)
8,264 (100.0%)
#DIV/0!
66,816 (100.0%)
15,342 (100.0%)
#DIV/0!
Acute MI; n (%)
31,334 (91.5%)
6,496 (91.8%)
-0.01
31,063 (95.4%)
7,831 (94.8%)
0.03
62397 (93.4%)
14327 (93.4%)
0.00
ACS/unstable angina; n (%)
14,701 (42.9%)
2,968 (41.9%)
0.02
11,618 (35.7%)
2,960 (35.8%)
0.00
26319 (39.4%)
5928 (38.6%)
0.02
Old MI; n (%)
5,865 (17.1%)
1,180 (16.7%)
0.01
3,170 (9.7%)
720 (8.7%)
0.03
9035 (13.5%)
1900 (12.4%)
0.03
Stable angina; n (%)
8,209 (24.0%)
1,781 (25.2%)
-0.03
4,741 (14.6%)
1,380 (16.7%)
-0.06
12,950 (19.4%)
3,161 (20.6%)
-0.03
Coronary atherosclerosis and other forms 
of chronic ischemic heart disease; n (%)
32,438 (94.7%)
6,799 (96.1%)
-0.07
29,092 (89.3%)
7,630 (92.3%)
-0.10
61,530 (92.1%)
14,429 (94.0%)
-0.07
Other atherosclerosis with ICD10  ; n (%)
634 (1.9%)
84 (1.2%)
0.06
632 (1.9%)
89 (1.1%)
0.07
1266 (1.9%)
173 (1.1%)
0.07
Previous cardiac procedure (CABG or PTCA 
or Stent) ; n (%)
25,241 (73.7%)
6,564 (92.7%)
-0.53
24,229 (74.4%)
7,510 (90.9%)
-0.45
49470 (74.0%)
14074 (91.7%)
-0.48
History of CABG or PTCA; n (%)
12,033 (35.1%)
2,459 (34.7%)
0.01
5,974 (18.3%)
1,489 (18.0%)
0.01
18,007 (27.0%)
3,948 (25.7%)
0.03
Any stroke; n (%)
4,738 (13.8%)
622 (8.8%)
0.16
3,006 (9.2%)
433 (5.2%)
0.16
7,744 (11.6%)
1,055 (6.9%)
0.16
Ischemic stroke (w and w/o mention of 
cerebral infarction); n (%)
4,698 (13.7%)
619 (8.7%)
0.16
2,999 (9.2%)
433 (5.2%)
0.16
7,697 (11.5%)
1,052 (6.9%)
0.16
Hemorrhagic stroke; n (%)
77 (0.2%)
8 (0.1%)
0.03
9 (0.0%)
0 (0.0%)
#DIV/0!
86 (0.1%)
8 (0.1%)
0.00
TIA; n (%)
829 (2.4%)
128 (1.8%)
0.04
595 (1.8%)
81 (1.0%)
0.07
1424 (2.1%)
209 (1.4%)
0.05
Other cerebrovascular disease; n (%)
1,088 (3.2%)
153 (2.2%)
0.06
565 (1.7%)
77 (0.9%)
0.07
1653 (2.5%)
230 (1.5%)
0.07
Late effects of cerebrovascular disease; n 
(%)
888 (2.6%)
139 (2.0%)
0.04
337 (1.0%)
54 (0.7%)
0.03
1225 (1.8%)
193 (1.3%)
0.04
Cerebrovascular procedure; n (%)
71 (0.2%)
8 (0.1%)
0.03
49 (0.2%)
4 (0.0%)
0.06
120 (0.2%)
12 (0.1%)
0.03
Heart failure (CHF); n (%)
10,773 (31.5%)
1,796 (25.4%)
0.14
7,073 (21.7%)
1,226 (14.8%)
0.18
17,846 (26.7%)
3,022 (19.7%)
0.17
Peripheral Vascular Disease (PVD) or PVD 
Surgery ; n (%)
4,708 (13.7%)
884 (12.5%)
0.04
2,400 (7.4%)
428 (5.2%)
0.09
7,108 (10.6%)
1,312 (8.6%)
0.07
Atrial fibrillation; n (%)
6,613 (19.3%)
833 (11.8%)
0.21
4,094 (12.6%)
587 (7.1%)
0.19
10,707 (16.0%)
1,420 (9.3%)
0.20
Other cardiac dysrhythmia; n (%)
13,828 (40.4%)
2,626 (37.1%)
0.07
9,711 (29.8%)
2,478 (30.0%)
0.00
23,539 (35.2%)
5,104 (33.3%)
0.04
Unmatched
Optum
Truven
POOLED
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Cardiac conduction disorders; n (%)
5,955 (17.4%)
1,074 (15.2%)
0.06
3,681 (11.3%)
813 (9.8%)
0.05
9636 (14.4%)
1887 (12.3%)
0.06
Other CVD; n (%)
14,535 (42.4%)
2,682 (37.9%)
0.09
9,954 (30.6%)
2,194 (26.5%)
0.09
24,489 (36.7%)
4,876 (31.8%)
0.10
Diabetes-related complications
Diabetic retinopathy; n (%)
1,230 (3.6%)
273 (3.9%)
-0.02
633 (1.9%)
154 (1.9%)
0.00
1,863 (2.8%)
0,427 (2.8%)
0.00
Diabetes with other ophthalmic 
manifestations; n (%)
105 (0.3%)
36 (0.5%)
-0.03
422 (1.3%)
75 (0.9%)
0.04
0,527 (0.8%)
0,111 (0.7%)
0.01
Retinal detachment, vitreous hemorrhage, 
vitrectomy; n (%)
147 (0.4%)
17 (0.2%)
0.04
74 (0.2%)
24 (0.3%)
-0.02
221 (0.3%)
41 (0.3%)
0.00
Retinal laser coagulation therapy; n (%)
127 (0.4%)
31 (0.4%)
0.00
113 (0.3%)
36 (0.4%)
-0.02
240 (0.4%)
67 (0.4%)
0.00
Occurrence of Diabetic Neuropathy  ; n (%)
3,634 (10.6%)
902 (12.7%)
-0.07
1,671 (5.1%)
430 (5.2%)
0.00
5,305 (7.9%)
1,332 (8.7%)
-0.03
Occurrence of diabetic nephropathy  with 
ICD10 ; n (%)
3,723 (10.9%)
859 (12.1%)
-0.04
1,057 (3.2%)
259 (3.1%)
0.01
4,780 (7.2%)
1,118 (7.3%)
0.00
Hypoglycemia ; n (%)
529 (1.5%)
40 (0.6%)
0.09
598 (1.8%)
96 (1.2%)
0.05
1,127 (1.7%)
0,136 (0.9%)
0.07
Hyperglycemia; n (%)
2,999 (8.8%)
639 (9.0%)
-0.01
1,715 (5.3%)
497 (6.0%)
-0.03
4,714 (7.1%)
1,136 (7.4%)
-0.01
Disorders of fluid electrolyte and acid-base 
balance; n (%)
7,300 (21.3%)
1,404 (19.8%)
0.04
3,644 (11.2%)
793 (9.6%)
0.05
10,944 (16.4%)
2,197 (14.3%)
0.06
Diabetic ketoacidosis; n (%)
217 (0.6%)
40 (0.6%)
0.00
189 (0.6%)
49 (0.6%)
0.00
406 (0.6%)
89 (0.6%)
0.00
Hyperosmolar hyperglycemic nonketotic 
syndrome (HONK); n (%)
154 (0.4%)
34 (0.5%)
-0.01
56 (0.2%)
13 (0.2%)
0.00
210 (0.3%)
47 (0.3%)
0.00
Diabetes with peripheral circulatory 
disorders with ICD-10  ; n (%)
1,964 (5.7%)
470 (6.6%)
-0.04
652 (2.0%)
145 (1.8%)
0.01
2,616 (3.9%)
0,615 (4.0%)
-0.01
Diabetic Foot; n (%)
655 (1.9%)
104 (1.5%)
0.03
412 (1.3%)
74 (0.9%)
0.04
1067 (1.6%)
178 (1.2%)
0.03
Gangrene ; n (%)
80 (0.2%)
9 (0.1%)
0.03
38 (0.1%)
4 (0.0%)
0.04
118 (0.2%)
13 (0.1%)
0.03
Lower extremity amputation; n (%)
258 (0.8%)
45 (0.6%)
0.02
70 (0.2%)
17 (0.2%)
0.00
328 (0.5%)
62 (0.4%)
0.01
Osteomyelitis; n (%)
144 (0.4%)
30 (0.4%)
0.00
88 (0.3%)
23 (0.3%)
0.00
232 (0.3%)
53 (0.3%)
0.00
Skin infections ; n (%)
1,789 (5.2%)
325 (4.6%)
0.03
1,272 (3.9%)
294 (3.6%)
0.02
3,061 (4.6%)
0,619 (4.0%)
0.03
Erectile dysfunction; n (%)
895 (2.6%)
230 (3.2%)
-0.04
634 (1.9%)
197 (2.4%)
-0.03
1,529 (2.3%)
0,427 (2.8%)
-0.03
Diabetes with unspecified complication; n 
(%)
1,412 (4.1%)
409 (5.8%)
-0.08
758 (2.3%)
278 (3.4%)
-0.07
2,170 (3.2%)
0,687 (4.5%)
-0.07
Diabetes mellitus without mention of 
complications; n (%)
15,987 (46.7%)
3,767 (53.2%)
-0.13
13,028 (40.0%)
3,410 (41.3%)
-0.03
29,015 (43.4%)
7,177 (46.8%)
-0.07
Hypertension: 1 inpatient or 2 outpatient 
claims within 365 days; n (%)
29,781 (86.9%)
6,140 (86.7%)
0.01
24,582 (75.5%)
6,362 (77.0%)
-0.04
54,363 (81.4%)
12,502 (81.5%)
0.00
Hyperlipidemia ; n (%)
28,216 (82.4%)
5,950 (84.1%)
-0.05
21,320 (65.5%)
5,887 (71.2%)
-0.12
49,536 (74.1%)
11,837 (77.2%)
-0.07
Edema; n (%)
2,760 (8.1%)
463 (6.5%)
0.06
1,232 (3.8%)
240 (2.9%)
0.05
3,992 (6.0%)
0,703 (4.6%)
0.06
Renal Dysfunction (non-diabetic) ; n (%)
10,997 (32.1%)
2,153 (30.4%)
0.04
5,565 (17.1%)
1,067 (12.9%)
0.12
16,562 (24.8%)
3,220 (21.0%)
0.09
Occurrence of acute renal disease ; n (%)
5,186 (15.1%)
967 (13.7%)
0.04
2,495 (7.7%)
464 (5.6%)
0.08
7681 (11.5%)
1431 (9.3%)
0.07
Occurrence of chronic renal insufficiency; 
n (%)
8,114 (23.7%)
1,581 (22.3%)
0.03
3,144 (9.7%)
565 (6.8%)
0.11
11,258 (16.8%)
2,146 (14.0%)
0.08
Chronic kidney disease ; n (%)
7,938 (23.2%)
1,541 (21.8%)
0.03
3,053 (9.4%)
537 (6.5%)
0.11
10,991 (16.4%)
2,078 (13.5%)
0.08
CKD Stage 3-4; n (%)
5,647 (16.5%)
1,103 (15.6%)
0.02
1,963 (6.0%)
358 (4.3%)
0.08
7,610 (11.4%)
1,461 (9.5%)
0.06
Occurrence of hypertensive nephropathy; 
n (%)
6,374 (18.6%)
1,237 (17.5%)
0.03
2,370 (7.3%)
390 (4.7%)
0.11
8744 (13.1%)
1627 (10.6%)
0.08
Occurrence of miscellaneous renal 
insufficiency ; n (%)
3,321 (9.7%)
626 (8.8%)
0.03
1,555 (4.8%)
344 (4.2%)
0.03
4,876 (7.3%)
0,970 (6.3%)
0.04
Glaucoma or cataracts ; n (%)
5,574 (16.3%)
1,117 (15.8%)
0.01
4,135 (12.7%)
898 (10.9%)
0.06
9,709 (14.5%)
2,015 (13.1%)
0.04
Cellulitis or abscess of toe; n (%)
474 (1.4%)
87 (1.2%)
0.02
184 (0.6%)
56 (0.7%)
-0.01
658 (1.0%)
143 (0.9%)
0.01
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Foot ulcer; n (%)
661 (1.9%)
107 (1.5%)
0.03
415 (1.3%)
72 (0.9%)
0.04
1076 (1.6%)
179 (1.2%)
0.03
Bladder stones; n (%)
78 (0.2%)
9 (0.1%)
0.03
30 (0.1%)
9 (0.1%)
0.00
108 (0.2%)
18 (0.1%)
0.03
Kidney stones; n (%)
961 (2.8%)
220 (3.1%)
-0.02
521 (1.6%)
148 (1.8%)
-0.02
1,482 (2.2%)
0,368 (2.4%)
-0.01
Urinary tract infections (UTIs); n (%)
3,662 (10.7%)
627 (8.9%)
0.06
1,767 (5.4%)
308 (3.7%)
0.08
5,429 (8.1%)
0,935 (6.1%)
0.08
Dipstick urinalysis; n (%)
9,527 (27.8%)
1,976 (27.9%)
0.00
6,727 (20.7%)
1,658 (20.1%)
0.01
16,254 (24.3%)
3,634 (23.7%)
0.01
Non-dipstick urinalysis; n (%)
5,596 (16.3%)
1,400 (19.8%)
-0.09
3,038 (9.3%)
864 (10.5%)
-0.04
8,634 (12.9%)
2,264 (14.8%)
-0.06
Urine function test; n (%)
867 (2.5%)
162 (2.3%)
0.01
619 (1.9%)
156 (1.9%)
0.00
1,486 (2.2%)
0,318 (2.1%)
0.01
Cytology; n (%)
410 (1.2%)
84 (1.2%)
0.00
179 (0.5%)
37 (0.4%)
0.01
589 (0.9%)
121 (0.8%)
0.01
Cystos; n (%)
597 (1.7%)
106 (1.5%)
0.02
233 (0.7%)
43 (0.5%)
0.03
830 (1.2%)
149 (1.0%)
0.02
Other Covariates
Liver disease; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0,000 (0.0%)
0,000 (0.0%)
#DIV/0!
Osteoarthritis; n (%)
7,052 (20.6%)
1,438 (20.3%)
0.01
4,240 (13.0%)
988 (12.0%)
0.03
11,292 (16.9%)
2,426 (15.8%)
0.03
Other arthritis, arthropathies and 
musculoskeletal pain; n (%)
13,667 (39.9%)
2,723 (38.5%)
0.03
10,227 (31.4%)
2,471 (29.9%)
0.03
23,894 (35.8%)
5,194 (33.9%)
0.04
Dorsopathies; n (%)
9,026 (26.4%)
1,846 (26.1%)
0.01
6,582 (20.2%)
1,668 (20.2%)
0.00
15,608 (23.4%)
3,514 (22.9%)
0.01
Fractures; n (%)
1,178 (3.4%)
202 (2.9%)
0.03
737 (2.3%)
153 (1.9%)
0.03
1,915 (2.9%)
0,355 (2.3%)
0.04
Falls ; n (%)
1,563 (4.6%)
267 (3.8%)
0.04
370 (1.1%)
70 (0.8%)
0.03
1933 (2.9%)
337 (2.2%)
0.04
Osteoporosis; n (%)
2,018 (5.9%)
328 (4.6%)
0.06
1,062 (3.3%)
164 (2.0%)
0.08
3,080 (4.6%)
0,492 (3.2%)
0.07
Hyperthyroidism; n (%)
239 (0.7%)
47 (0.7%)
0.00
134 (0.4%)
29 (0.4%)
0.00
373 (0.6%)
76 (0.5%)
0.01
Hypothyroidism ; n (%)
5,722 (16.7%)
1,155 (16.3%)
0.01
3,460 (10.6%)
809 (9.8%)
0.03
9,182 (13.7%)
1,964 (12.8%)
0.03
Other disorders of thyroid gland ; n (%)
1,009 (2.9%)
246 (3.5%)
-0.03
684 (2.1%)
176 (2.1%)
0.00
1,693 (2.5%)
0,422 (2.8%)
-0.02
Depression; n (%)
4,071 (11.9%)
818 (11.6%)
0.01
2,357 (7.2%)
499 (6.0%)
0.05
6,428 (9.6%)
1,317 (8.6%)
0.03
Anxiety; n (%)
4,488 (13.1%)
986 (13.9%)
-0.02
2,477 (7.6%)
682 (8.3%)
-0.03
6,965 (10.4%)
1,668 (10.9%)
-0.02
SleepDisorder; n (%)
2,233 (6.5%)
322 (4.5%)
0.09
2,524 (7.8%)
461 (5.6%)
0.09
4,757 (7.1%)
0,783 (5.1%)
0.08
Dementia; n (%)
2,499 (7.3%)
310 (4.4%)
0.12
1,211 (3.7%)
120 (1.5%)
0.14
3710 (5.6%)
430 (2.8%)
0.14
Delirium; n (%)
1,054 (3.1%)
159 (2.2%)
0.06
505 (1.6%)
73 (0.9%)
0.06
1559 (2.3%)
232 (1.5%)
0.06
Psychosis; n (%)
499 (1.5%)
64 (0.9%)
0.06
252 (0.8%)
37 (0.4%)
0.05
751 (1.1%)
101 (0.7%)
0.04
Obesity; n (%)
7,787 (22.7%)
1,982 (28.0%)
-0.12
5,186 (15.9%)
1,595 (19.3%)
-0.09
12,973 (19.4%)
3,577 (23.3%)
-0.10
Overweight; n (%)
1,859 (5.4%)
522 (7.4%)
-0.08
666 (2.0%)
250 (3.0%)
-0.06
2,525 (3.8%)
0,772 (5.0%)
-0.06
Smoking; n (%)
14,843 (43.3%)
3,268 (46.2%)
-0.06
8,437 (25.9%)
2,368 (28.7%)
-0.06
23,280 (34.8%)
5,636 (36.7%)
-0.04
Alcohol abuse or dependence; n (%)
838 (2.4%)
166 (2.3%)
0.01
556 (1.7%)
122 (1.5%)
0.02
1394 (2.1%)
288 (1.9%)
0.01
Drug abuse or dependence; n (%)
883 (2.6%)
198 (2.8%)
-0.01
380 (1.2%)
105 (1.3%)
-0.01
1263 (1.9%)
303 (2.0%)
-0.01
COPD; n (%)
7,224 (21.1%)
1,272 (18.0%)
0.08
4,050 (12.4%)
686 (8.3%)
0.13
11,274 (16.9%)
1,958 (12.8%)
0.12
Asthma; n (%)
2,569 (7.5%)
519 (7.3%)
0.01
1,779 (5.5%)
406 (4.9%)
0.03
4,348 (6.5%)
0,925 (6.0%)
0.02
Obstructive sleep apnea; n (%)
3,355 (9.8%)
841 (11.9%)
-0.07
2,502 (7.7%)
709 (8.6%)
-0.03
5,857 (8.8%)
1,550 (10.1%)
-0.04
Pneumonia; n (%)
2,786 (8.1%)
472 (6.7%)
0.05
1,673 (5.1%)
234 (2.8%)
0.12
4,459 (6.7%)
0,706 (4.6%)
0.09
Imaging; n (%)
835 (2.4%)
216 (3.1%)
-0.04
4,135 (12.7%)
113 (1.4%)
0.45
1227 (1.8%)
329 (2.1%)
-0.02
Other Medications
Use of ACE inhibitors; n (%)
18,168 (53.0%)
3,711 (52.4%)
0.01
18,195 (55.9%)
4,684 (56.7%)
-0.02
36,363 (54.4%)
8,395 (54.7%)
-0.01
Use of ARBs; n (%)
7,250 (21.2%)
1,772 (25.0%)
-0.09
6,486 (19.9%)
1,768 (21.4%)
-0.04
13,736 (20.6%)
3,540 (23.1%)
-0.06
Use of Loop Diuretics - ; n (%)
7,459 (21.8%)
1,065 (15.0%)
0.18
5,065 (15.6%)
615 (7.4%)
0.26
12,524 (18.7%)
1,680 (11.0%)
0.22
Use of other diuretics- ; n (%)
1,797 (5.2%)
346 (4.9%)
0.01
1,516 (4.7%)
346 (4.2%)
0.02
3,313 (5.0%)
0,692 (4.5%)
0.02
Use of nitrates-; n (%)
15,391 (44.9%)
3,062 (43.3%)
0.03
15,249 (46.8%)
3,618 (43.8%)
0.06
30,640 (45.9%)
6,680 (43.5%)
0.05
Use of other hypertension drugs; n (%)
3,062 (8.9%)
529 (7.5%)
0.05
2,130 (6.5%)
372 (4.5%)
0.09
5,192 (7.8%)
0,901 (5.9%)
0.08
Use of digoxin- ; n (%)
772 (2.3%)
72 (1.0%)
0.10
703 (2.2%)
64 (0.8%)
0.12
1475 (2.2%)
136 (0.9%)
0.11
Use of Anti-arrhythmics; n (%)
1,992 (5.8%)
204 (2.9%)
0.14
1,521 (4.7%)
157 (1.9%)
0.16
3513 (5.3%)
361 (2.4%)
0.15
Use of COPD/asthma meds- ; n (%)
5,251 (15.3%)
1,080 (15.3%)
0.00
4,557 (14.0%)
990 (12.0%)
0.06
9,808 (14.7%)
2,070 (13.5%)
0.03
Use of statins; n (%)
30,368 (88.7%)
6,399 (90.4%)
-0.06
29,034 (89.2%)
7,587 (91.8%)
-0.09
59,402 (88.9%)
13,986 (91.2%)
-0.08
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Use of other lipid-lowering drugs; n (%)
2,561 (7.5%)
545 (7.7%)
-0.01
2,974 (9.1%)
754 (9.1%)
0.00
5,535 (8.3%)
1,299 (8.5%)
-0.01
Use of oral anticoagulants (Dabigatran, 
Rivaroxaban, Apixaban, Warfarin); n (%)
3,350 (9.8%)
353 (5.0%)
0.18
2,682 (8.2%)
321 (3.9%)
0.18
6,032 (9.0%)
0,674 (4.4%)
0.18
Use of heparin and other low-molecular 
weight heparins; n (%)
384 (1.1%)
41 (0.6%)
0.05
3 (0.0%)
0 (0.0%)
#DIV/0!
387 (0.6%)
41 (0.3%)
0.04
Use of NSAIDs; n (%)
4,499 (13.1%)
1,078 (15.2%)
-0.06
4,253 (13.1%)
1,298 (15.7%)
-0.07
8,752 (13.1%)
2,376 (15.5%)
-0.07
Use of oral corticosteroids; n (%)
6,426 (18.8%)
1,272 (18.0%)
0.02
5,175 (15.9%)
1,257 (15.2%)
0.02
11,601 (17.4%)
2,529 (16.5%)
0.02
Use of bisphosphonate (); n (%)
783 (2.3%)
114 (1.6%)
0.05
554 (1.7%)
67 (0.8%)
0.08
1337 (2.0%)
181 (1.2%)
0.06
Use of opioids- ; n (%)
10,025 (29.3%)
1,741 (24.6%)
0.11
8,554 (26.3%)
1,758 (21.3%)
0.12
18,579 (27.8%)
3,499 (22.8%)
0.12
Use of antidepressants; n (%)
6,765 (19.8%)
1,410 (19.9%)
0.00
5,528 (17.0%)
1,302 (15.8%)
0.03
12,293 (18.4%)
2,712 (17.7%)
0.02
Use of antipsychotics; n (%)
665 (1.9%)
145 (2.0%)
-0.01
418 (1.3%)
74 (0.9%)
0.04
1,083 (1.6%)
0,219 (1.4%)
0.02
Use of anticonvulsants; n (%)
4,151 (12.1%)
968 (13.7%)
-0.05
2,669 (8.2%)
652 (7.9%)
0.01
6,820 (10.2%)
1,620 (10.6%)
-0.01
Use of lithium- ; n (%)
41 (0.1%)
11 (0.2%)
-0.03
35 (0.1%)
6 (0.1%)
0.00
76 (0.1%)
17 (0.1%)
0.00
Use of Benzos- ; n (%)
3,677 (10.7%)
793 (11.2%)
-0.02
3,590 (11.0%)
852 (10.3%)
0.02
7,267 (10.9%)
1,645 (10.7%)
0.01
Use of anxiolytics/hypnotics- ; n (%)
1,644 (4.8%)
316 (4.5%)
0.01
1,835 (5.6%)
441 (5.3%)
0.01
3,479 (5.2%)
0,757 (4.9%)
0.01
Use of dementia meds- ; n (%)
924 (2.7%)
123 (1.7%)
0.07
648 (2.0%)
61 (0.7%)
0.11
1572 (2.4%)
184 (1.2%)
0.09
Use of antiparkinsonian meds- ; n (%)
805 (2.4%)
159 (2.2%)
0.01
576 (1.8%)
117 (1.4%)
0.03
1,381 (2.1%)
0,276 (1.8%)
0.02
Entresto (sacubitril/valsartan); n (%)
58 (0.2%)
16 (0.2%)
0.00
9 (0.0%)
3 (0.0%)
#DIV/0!
67 (0.1%)
19 (0.1%)
0.00
Labs
0
0
Lab values- HbA1c (%) ; n (%)
5,587 (16.3%)
1,481 (20.9%)
-0.12
570 (1.8%)
128 (1.5%)
0.02
6,157 (9.2%)
1,609 (10.5%)
-0.04
Lab values- HbA1c (%) (within 3 months) ; n 
(%)
3,598 (10.5%)
955 (13.5%)
-0.09
395 (1.2%)
93 (1.1%)
0.01
3,993 (6.0%)
1,048 (6.8%)
-0.03
Lab values- HbA1c (%) (within 6 months) ; n 
(%)
5,587 (16.3%)
1,481 (20.9%)
-0.12
570 (1.8%)
128 (1.5%)
0.02
6,157 (9.2%)
1,609 (10.5%)
-0.04
Lab values- BNP; n (%)
376 (1.1%)
75 (1.1%)
0.00
44 (0.1%)
2 (0.0%)
0.04
420 (0.6%)
77 (0.5%)
0.01
Lab values- BNP (within 3 months); n (%)
290 (0.8%)
54 (0.8%)
0.00
39 (0.1%)
1 (0.0%)
0.04
329 (0.5%)
55 (0.4%)
0.01
Lab values- BNP (within 6 months); n (%)
376 (1.1%)
75 (1.1%)
0.00
44 (0.1%)
2 (0.0%)
0.04
420 (0.6%)
77 (0.5%)
0.01
Lab values- BUN (mg/dl); n (%)
8,281 (24.2%)
2,014 (28.5%)
-0.10
452 (1.4%)
141 (1.7%)
-0.02
8,733 (13.1%)
2,155 (14.0%)
-0.03
Lab values- BUN (mg/dl) (within 3 months); 
n (%)
5,410 (15.8%)
1,335 (18.9%)
-0.08
310 (1.0%)
88 (1.1%)
-0.01
5,720 (8.6%)
1,423 (9.3%)
-0.02
Lab values- BUN (mg/dl) (within 6 months); 
n (%)
8,281 (24.2%)
2,014 (28.5%)
-0.10
452 (1.4%)
141 (1.7%)
-0.02
8,733 (13.1%)
2,155 (14.0%)
-0.03
Lab values- Creatinine (mg/dl) ; n (%)
8,490 (24.8%)
2,074 (29.3%)
-0.10
475 (1.5%)
152 (1.8%)
-0.02
8,965 (13.4%)
2,226 (14.5%)
-0.03
Lab values- Creatinine (mg/dl) (within 3 
months) ; n (%)
5,559 (16.2%)
1,382 (19.5%)
-0.09
322 (1.0%)
98 (1.2%)
-0.02
5,881 (8.8%)
1,480 (9.6%)
-0.03
Lab values- Creatinine (mg/dl) (within 6 
months) ; n (%)
8,490 (24.8%)
2,074 (29.3%)
-0.10
475 (1.5%)
152 (1.8%)
-0.02
8,965 (13.4%)
2,226 (14.5%)
-0.03
Lab values- HDL level (mg/dl); n (%)
6,291 (18.4%)
1,583 (22.4%)
-0.10
482 (1.5%)
121 (1.5%)
0.00
6,773 (10.1%)
1,704 (11.1%)
-0.03
Lab values- HDL level (mg/dl) (within 3 
months); n (%)
3,750 (10.9%)
955 (13.5%)
-0.08
304 (0.9%)
71 (0.9%)
0.00
4,054 (6.1%)
1,026 (6.7%)
-0.02
Lab values- HDL level (mg/dl) (within 6 
months); n (%)
6,291 (18.4%)
1,583 (22.4%)
-0.10
482 (1.5%)
121 (1.5%)
0.00
6,773 (10.1%)
1,704 (11.1%)
-0.03
Lab values- LDL level (mg/dl) ; n (%)
6,448 (18.8%)
1,656 (23.4%)
-0.11
546 (1.7%)
129 (1.6%)
0.01
6,994 (10.5%)
1,785 (11.6%)
-0.04
Lab values- LDL level (mg/dl) (within 3 
months) ; n (%)
3,851 (11.2%)
1,012 (14.3%)
-0.09
367 (1.1%)
78 (0.9%)
0.02
4,218 (6.3%)
1,090 (7.1%)
-0.03
Lab values- LDL level (mg/dl) (within 6 
months) ; n (%)
6,448 (18.8%)
1,656 (23.4%)
-0.11
546 (1.7%)
129 (1.6%)
0.01
6,994 (10.5%)
1,785 (11.6%)
-0.04
Lab values- NT-proBNP; n (%)
61 (0.2%)
11 (0.2%)
0.00
1 (0.0%)
1 (0.0%)
#DIV/0!
62 (0.1%)
12 (0.1%)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Lab values- NT-proBNP (within 3 months); 
n (%)
47 (0.1%)
7 (0.1%)
0.00
1 (0.0%)
1 (0.0%)
#DIV/0!
48 (0.1%)
8 (0.1%)
0.00
Lab values- NT-proBNP (within 6 months); 
n (%)
61 (0.2%)
11 (0.2%)
0.00
1 (0.0%)
1 (0.0%)
#DIV/0!
62 (0.1%)
12 (0.1%)
0.00
Lab values- Total cholesterol (mg/dl) ; n (%)
6,353 (18.5%)
1,612 (22.8%)
-0.11
471 (1.4%)
123 (1.5%)
-0.01
6,824 (10.2%)
1,735 (11.3%)
-0.04
Lab values- Total cholesterol (mg/dl) 
(within 3 months) ; n (%)
3,786 (11.1%)
970 (13.7%)
-0.08
298 (0.9%)
71 (0.9%)
0.00
4,084 (6.1%)
1,041 (6.8%)
-0.03
Lab values- Total cholesterol (mg/dl) 
(within 6 months) ; n (%)
6,353 (18.5%)
1,612 (22.8%)
-0.11
471 (1.4%)
123 (1.5%)
-0.01
6,824 (10.2%)
1,735 (11.3%)
-0.04
Lab values- Triglyceride level (mg/dl); n (%)
6,221 (18.2%)
1,597 (22.6%)
-0.11
472 (1.4%)
119 (1.4%)
0.00
6,693 (10.0%)
1,716 (11.2%)
-0.04
Lab values- Triglyceride level (mg/dl) 
(within 3 months); n (%)
3,695 (10.8%)
963 (13.6%)
-0.09
296 (0.9%)
70 (0.8%)
0.01
3,991 (6.0%)
1,033 (6.7%)
-0.03
Lab values- Triglyceride level (mg/dl) 
(within 6 months); n (%)
6,221 (18.2%)
1,597 (22.6%)
-0.11
472 (1.4%)
119 (1.4%)
0.00
6,693 (10.0%)
1,716 (11.2%)
-0.04
Lab result number- HbA1c (%) mean (only 2 
to 20 included) 
                                     5,556                                      1,478 
                                       464                                        125 
0
0
...mean (sd)
7.20 (1.75)
7.29 (1.78)
-0.05
8.06 (1.91)
7.73 (1.79)
0.18
7.62 (1.83)
7.53 (1.79)
0.05
...median [IQR]
6.70 [6.00, 7.90]
6.80 [6.00, 8.08]
-0.06
7.55 [6.60, 9.20]
7.30 [6.30, 9.00]
0.14
7.11 (1.83)
7.07 (1.79)
0.02
...Missing; n (%)
28,695 (83.8%)
5,600 (79.1%)
0.12
32,101 (98.6%)
8,139 (98.5%)
0.01
60,796 (91.0%)
13,739 (89.6%)
0.05
Lab result number- BNP mean 
                                          376                                              75 
                                          44                                              2 
0
0
...mean (sd)
527.10 (1,591.70)
345.44 (674.53)
0.15
900.99 (2,781.11)
334.50 (0.71)
0.29
709.33 (2251.31)
339.55 (458.16)
0.23
...median [IQR]
163.50 [67.92, 
456.20]
99.00 [44.50, 280.00]
0.05
180.00 [51.75, 
426.75]
334.50 [334.00, 
335.00]
-0.08
171.54 (2251.31)
225.85 (458.16)
-0.03
...Missing; n (%)
33,875 (98.9%)
7,003 (98.9%)
0.00
32,521 (99.9%)
8,262 (100.0%)
-0.04
66,396 (99.4%)
15,265 (99.5%)
-0.01
Lab result number- BUN (mg/dl) mean 
                                     8,281                                      2,014 
                                       452                                        141 
0
0
...mean (sd)
19.75 (9.07)
18.87 (7.63)
0.10
571.73 (8,364.27)
2,768.72 (19,247.11)
-0.15
288.78 (5839.34)
1500.08 (14126.08)
-0.11
...median [IQR]
18.00 [14.00, 23.00]
17.00 [14.00, 22.00]
0.12
17.00 [14.00, 21.46]
17.00 [13.50, 21.00]
0.00
17.51 (5839.34)
17.00 (14126.08)
0.00
...Missing; n (%)
25,970 (75.8%)
5,064 (71.5%)
0.10
32,113 (98.6%)
8,123 (98.3%)
0.02
58,083 (86.9%)
13,187 (86.0%)
0.03
Lab result number- Creatinine (mg/dl) 
mean (only 0.1 to 15 included) 
                                     8,378                                      2,055 
                                       426                                        124 
0
0
...mean (sd)
1.11 (0.46)
1.08 (0.40)
0.07
1.05 (0.59)
1.00 (0.23)
0.11
1.08 (0.53)
1.04 (0.32)
0.09
...median [IQR]
1.01 [0.85, 1.24]
1.00 [0.84, 1.21]
0.02
0.98 [0.83, 1.12]
1.00 [0.88, 1.08]
-0.04
1.00 (0.53)
1.00 (0.32)
0.00
...Missing; n (%)
25,873 (75.5%)
5,023 (71.0%)
0.10
32,139 (98.7%)
8,140 (98.5%)
0.02
58,012 (86.8%)
13,163 (85.8%)
0.03
Lab result number- HDL level (mg/dl) mean 
(only =<5000 included) 
                                     6,291                                      1,583 
                                       480                                        121 
0
0
...mean (sd)
47.14 (15.16)
46.42 (13.96)
0.05
41.22 (13.28)
42.43 (12.34)
-0.09
44.25 (14.27)
44.27 (13.11)
0.00
...median [IQR]
45.00 [37.00, 55.00]
44.00 [37.00, 54.00]
0.07
40.00 [34.00, 49.00]
40.00 [35.00, 50.00]
0.00
42.56 (14.27)
41.85 (13.11)
0.05
...Missing; n (%)
27,960 (81.6%)
5,495 (77.6%)
0.10
32,085 (98.5%)
8,143 (98.5%)
0.00
60,045 (89.9%)
13,638 (88.9%)
0.03
Lab result number- LDL level (mg/dl) mean 
(only =<5000 included) 
                                     6,290                                      1,620 
                                       465                                        114 
0
0
...mean (sd)
99.66 (43.64)
103.21 (43.70)
-0.08
95.58 (49.98)
97.40 (47.25)
-0.04
97.67 (46.84)
100.08 (45.65)
-0.05
...median [IQR]
97.00 [72.00, 126.00]
100.00 [75.00, 
130.00]
-0.07
92.00 [66.00, 
125.75]
104.00 [61.75, 
130.38]
-0.25
94.56 (46.84)
102.15 (45.65)
-0.16
...Missing; n (%)
27,961 (81.6%)
5,458 (77.1%)
0.11
32,100 (98.6%)
8,150 (98.6%)
0.00
60,061 (89.9%)
13,608 (88.7%)
0.04
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Lab result number- Total cholesterol 
(mg/dl) mean (only =<5000 included) 
                                     6,335                                      1,608 
                                       469                                        122 
0
0
...mean (sd)
183.83 (52.62)
187.10 (48.78)
-0.06
181.89 (60.15)
191.08 (49.85)
-0.17
182.88 (56.42)
189.24 (49.36)
-0.12
...median [IQR]
178.00 [150.00, 
211.00]
182.00 [154.00, 
216.00]
-0.08
178.00 [145.25, 
215.50]
190.00 [158.00, 
223.50]
-0.22
178.00 (56.42)
186.31 (49.36)
-0.16
...Missing; n (%)
27,916 (81.5%)
5,470 (77.3%)
0.10
32,096 (98.6%)
8,142 (98.5%)
0.01
60,012 (89.8%)
13,612 (88.7%)
0.04
Lab result number- Triglyceride level 
(mg/dl) mean (only =<5000 included) 
                                     6,217                                      1,597 
                                       470                                        118 
0
0
...mean (sd)
167.43 (139.68)
173.67 (120.45)
-0.05
192.52 (165.88)
209.43 (138.42)
-0.11
179.66 (153.01)
192.93 (130.44)
-0.09
...median [IQR]
136.00 [97.00, 
195.50]
144.50 [105.00, 
206.00]
-0.07
157.33 [109.00, 
214.50]
167.00 [131.75, 
247.75]
-0.06
146.40 (153.01)
156.62 (130.44)
-0.07
...Missing; n (%)
28,034 (81.8%)
5,481 (77.4%)
0.11
32,095 (98.6%)
8,146 (98.6%)
0.00
60,129 (90.0%)
13,627 (88.8%)
0.04
Lab result number- Hemoglobin mean 
(only >0 included)
                                     6,311                                      1,527 
                                       322                                           91 
0
0
...mean (sd)
13.63 (1.82)
13.86 (1.78)
-0.13
13.56 (2.07)
111,610.08 
(1,048,228.73)
-0.15
13.60 (1.95)
60125.39 
(769329.27)
-0.11
...median [IQR]
13.70 [12.40, 14.90]
14.00 [12.67, 15.10]
-0.17
13.70 [12.50, 15.00]
14.30 [13.00, 15.00]
0.00
13.70 (1.95)
14.16 (769329.27)
0.00
...Missing; n (%)
27,940 (81.6%)
5,551 (78.4%)
0.08
32,243 (99.0%)
8,173 (98.9%)
0.01
60,183 (90.1%)
13,724 (89.5%)
0.02
Lab result number- Serum sodium mean 
(only > 90 and < 190 included)
                                     8,155                                      2,011 
                                       425                                        137 
0
0
...mean (sd)
139.83 (2.95)
140.07 (2.79)
-0.08
138.91 (2.74)
139.30 (2.58)
-0.15
139.38 (2.85)
139.66 (2.68)
-0.10
...median [IQR]
140.00 [138.00, 
142.00]
140.00 [138.50, 
142.00]
0.00
139.00 [137.00, 
141.00]
139.50 [137.75, 
141.00]
-0.19
139.51 (2.85)
139.73 (2.68)
-0.08
...Missing; n (%)
26,096 (76.2%)
5,067 (71.6%)
0.10
32,140 (98.7%)
8,127 (98.3%)
0.03
58,236 (87.2%)
13,194 (86.0%)
0.04
Lab result number- Albumin mean (only >0 
and <=10 included)
                                     7,380                                      1,825 
                                       361                                        118 
0
0
...mean (sd)
4.16 (0.35)
4.21 (0.34)
-0.14
4.04 (0.65)
4.01 (0.48)
0.05
4.10 (0.52)
4.10 (0.42)
0.00
...median [IQR]
4.20 [4.00, 4.40]
4.20 [4.00, 4.40]
0.00
4.10 [4.00, 4.40]
4.00 [4.00, 4.30]
0.18
4.15 (0.52)
4.09 (0.42)
0.13
...Missing; n (%)
26,871 (78.5%)
5,253 (74.2%)
0.10
32,204 (98.9%)
8,146 (98.6%)
0.03
59,075 (88.4%)
13,399 (87.3%)
0.03
Lab result number- Glucose (fasting or 
random) mean (only 10-1000 included)
                                     8,076                                      2,007 
                                       418                                        139 
0
0
...mean (sd)
131.19 (59.23)
135.47 (61.82)
-0.07
166.36 (68.04)
156.18 (62.58)
0.16
148.33 (63.68)
146.63 (62.23)
0.03
...median [IQR]
110.50 [95.00, 
146.38]
114.00 [97.00, 
152.50]
-0.06
148.17 [117.50, 
193.17]
142.00 [111.00, 
188.00]
0.09
128.86 (63.68)
129.08 (62.23)
0.00
...Missing; n (%)
26,175 (76.4%)
5,071 (71.6%)
0.11
32,147 (98.7%)
8,125 (98.3%)
0.03
58,322 (87.3%)
13,196 (86.0%)
0.04
Lab result number- Potassium mean (only 
1-7 included)
                                     8,373                                      2,050 
                                       437                                        133 
0
0
...mean (sd)
4.42 (0.45)
4.46 (0.44)
-0.09
4.32 (0.48)
4.16 (0.44)
0.35
4.37 (0.46)
4.30 (0.44)
0.16
...median [IQR]
4.40 [4.10, 4.70]
4.44 [4.20, 4.70]
-0.09
4.30 [4.00, 4.60]
4.10 [4.00, 4.40]
0.43
4.35 (0.46)
4.26 (0.44)
0.20
...Missing; n (%)
25,878 (75.6%)
5,028 (71.0%)
0.10
32,128 (98.7%)
8,131 (98.4%)
0.03
58,006 (86.8%)
13,159 (85.8%)
0.03
Comorbidity Scores
CCI (180 days)- ICD9 and ICD10 
...mean (sd)
4.00 (2.59)
3.69 (2.41)
0.12
2.50 (1.89)
2.21 (1.61)
0.17
3.27 (2.28)
2.89 (2.02)
0.18
...median [IQR]
4.00 [2.00, 6.00]
3.00 [2.00, 5.00]
0.40
2.00 [1.00, 4.00]
2.00 [1.00, 3.00]
0.00
3.03 (2.28)
2.46 (2.02)
0.26
Frailty Score (mean): Empirical Version 365 
days, 
...mean (sd)
0.20 (0.06)
0.20 (0.05)
0.00
0.18 (0.05)
0.18 (0.04)
0.00
0.19 (0.06)
0.19 (0.04)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

...median [IQR]
0.19 [0.17, 0.23]
0.19 [0.16, 0.22]
0.00
0.18 [0.15, 0.20]
0.17 [0.15, 0.19]
0.22
0.19 (0.06)
0.18 (0.04)
0.20
Healthcare Utilization
Any hospitalization; n (%)
34,191 (99.8%)
7,071 (99.9%)
-0.03
32,565 (100.0%)
8,264 (100.0%)
#DIV/0!
66,756 (99.9%)
15,335 (100.0%)
-0.04
Any hospitalization during prior 31-180 
days; n (%)
2,482 (7.2%)
418 (5.9%)
0.05
1,256 (3.9%)
199 (2.4%)
0.09
3,738 (5.6%)
0,617 (4.0%)
0.07
Endocrinologist Visit; n (%)
2,043 (6.0%)
497 (7.0%)
-0.04
1,587 (4.9%)
464 (5.6%)
-0.03
3,630 (5.4%)
0,961 (6.3%)
-0.04
Endocrinologist Visit (30 days prior); n (%)
1,167 (3.4%)
255 (3.6%)
-0.01
910 (2.8%)
244 (3.0%)
-0.01
2,077 (3.1%)
0,499 (3.3%)
-0.01
Endocrinologist Visit (31 to 180 days 
prior); n (%)
1,161 (3.4%)
321 (4.5%)
-0.06
877 (2.7%)
286 (3.5%)
-0.05
2,038 (3.1%)
0,607 (4.0%)
-0.05
Internal medicine/family medicine visits; n 
(%)
29,770 (86.9%)
6,033 (85.2%)
0.05
23,203 (71.3%)
5,917 (71.6%)
-0.01
52,973 (79.3%)
11,950 (77.9%)
0.03
Internal medicine/family medicine visits 
(30 days prior) ; n (%)
25,267 (73.8%)
5,047 (71.3%)
0.06
15,093 (46.3%)
3,669 (44.4%)
0.04
40,360 (60.4%)
8,716 (56.8%)
0.07
Internal medicine/family medicine visits 
(31 to 180 days prior) ; n (%)
22,710 (66.3%)
4,564 (64.5%)
0.04
18,942 (58.2%)
4,760 (57.6%)
0.01
41,652 (62.3%)
9,324 (60.8%)
0.03
Cardiologist visit; n (%)
31,825 (92.9%)
6,595 (93.2%)
-0.01
12,667 (38.9%)
3,160 (38.2%)
0.01
44,492 (66.6%)
9,755 (63.6%)
0.06
Number of Cardiologist visits (30 days 
prior); n (%)
31,454 (91.8%)
6,555 (92.6%)
-0.03
10,251 (31.5%)
2,599 (31.4%)
0.00
41,705 (62.4%)
9,154 (59.7%)
0.06
Number of Cardiologist visits (31 to 180 
days prior); n (%)
8,575 (25.0%)
1,530 (21.6%)
0.08
4,839 (14.9%)
1,058 (12.8%)
0.06
13,414 (20.1%)
2,588 (16.9%)
0.08
Electrocardiogram ; n (%)
32,129 (93.8%)
6,630 (93.7%)
0.00
19,485 (59.8%)
4,518 (54.7%)
0.10
51,614 (77.2%)
11,148 (72.7%)
0.10
Use of glucose test strips; n (%)
610 (1.8%)
134 (1.9%)
-0.01
427 (1.3%)
124 (1.5%)
-0.02
1,037 (1.6%)
0,258 (1.7%)
-0.01
Dialysis; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
number of different/distinct medication 
prescriptions
...mean (sd)
10.48 (5.03)
10.47 (5.09)
0.00
9.73 (4.54)
9.33 (4.39)
0.09
10.11 (4.80)
9.86 (4.73)
0.05
...median [IQR]
10.00 [7.00, 13.00]
10.00 [7.00, 13.00]
0.00
9.00 [6.00, 12.00]
9.00 [6.00, 12.00]
0.00
9.51 (4.80)
9.46 (4.73)
0.01
Number of Hospitalizations
...mean (sd)
1.17 (0.48)
1.13 (0.44)
0.09
1.10 (0.35)
1.06 (0.26)
0.13
1.14 (0.42)
1.09 (0.35)
0.13
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 (0.42)
1.00 (0.35)
0.00
Number of hospital days
...mean (sd)
5.07 (4.30)
4.37 (3.53)
0.18
4.34 (3.10)
3.58 (2.06)
0.29
4.71 (3.76)
3.94 (2.83)
0.23
...median [IQR]
4.00 [3.00, 6.00]
3.00 [3.00, 5.00]
0.25
3.00 [3.00, 5.00]
3.00 [3.00, 4.00]
0.00
3.51 (3.76)
3.00 (2.83)
0.15
Number of Emergency Department (ED) 
visits 
...mean (sd)
1.26 (1.65)
1.17 (1.73)
0.05
3.03 (5.26)
3.33 (5.85)
-0.05
2.12 (3.86)
2.33 (4.45)
-0.05
...median [IQR]
1.00 [0.00, 2.00]
1.00 [0.00, 1.00]
0.00
2.00 [0.00, 4.00]
2.00 [0.00, 4.00]
0.00
1.49 (3.86)
1.54 (4.45)
-0.01
Number of Office visits
...mean (sd)
4.08 (3.94)
3.98 (3.73)
0.03
3.39 (3.56)
3.06 (3.22)
0.10
3.74 (3.76)
3.48 (3.46)
0.07
...median [IQR]
3.00 [1.00, 6.00]
3.00 [1.00, 6.00]
0.00
2.00 [1.00, 5.00]
2.00 [1.00, 4.00]
0.00
2.51 (3.76)
2.46 (3.46)
0.01
Number of Endocrinologist visits
...mean (sd)
0.26 (1.62)
0.30 (1.89)
-0.02
0.21 (1.33)
0.24 (1.51)
-0.02
0.75 (1.50)
0.67 (1.62)
0.05
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.51 (1.50)
0.46 (1.62)
0.03
Number of internal medicine/family 
medicine visits
...mean (sd)
10.38 (14.10)
9.76 (13.28)
0.05
5.01 (8.06)
4.54 (7.21)
0.06
7.76 (11.56)
6.95 (10.46)
0.07
...median [IQR]
6.00 [2.00, 13.00]
6.00 [2.00, 12.00]
0.00
3.00 [0.00, 6.00]
2.00 [0.00, 6.00]
0.13
4.54 (11.56)
3.85 (10.46)
0.06
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Number of Cardiologist visits
...mean (sd)
9.25 (6.90)
9.65 (6.77)
-0.06
1.38 (2.87)
1.29 (2.61)
0.03
5.41 (5.33)
5.15 (4.98)
0.05
...median [IQR]
8.00 [5.00, 12.00]
9.00 [6.00, 12.00]
-0.15
0.00 [0.00, 2.00]
0.00 [0.00, 2.00]
0.00
4.10 (5.33)
4.15 (4.98)
-0.01
Number electrocardiograms received 
...mean (sd)
3.66 (3.02)
3.56 (2.99)
0.03
1.26 (1.60)
1.08 (1.47)
0.12
2.49 (2.43)
2.22 (2.30)
0.11
...median [IQR]
3.00 [2.00, 5.00]
3.00 [2.00, 5.00]
0.00
1.00 [0.00, 2.00]
1.00 [0.00, 2.00]
0.00
2.03 (2.43)
1.92 (2.30)
0.05
Number of HbA1c tests ordered
...mean (sd)
0.47 (0.76)
0.55 (0.79)
-0.10
0.28 (0.60)
0.34 (0.65)
-0.10
0.38 (0.69)
0.44 (0.72)
-0.09
...median [IQR]
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 1.00]
0.00
0.00 (0.69)
0.00 (0.72)
0.00
Number of glucose tests ordered
...mean (sd)
0.27 (2.79)
0.30 (2.78)
-0.01
0.16 (0.78)
0.16 (0.96)
0.00
0.22 (2.07)
0.22 (2.02)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (2.07)
0.00 (2.02)
0.00
Number of lipid tests ordered
...mean (sd)
0.58 (0.81)
0.61 (0.80)
-0.04
0.39 (0.83)
0.44 (0.85)
-0.06
0.49 (0.82)
0.52 (0.83)
-0.04
...median [IQR]
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 (0.82)
0.00 (0.83)
0.00
Number of creatinine tests ordered
...mean (sd)
0.06 (0.33)
0.06 (0.34)
0.00
0.06 (0.33)
0.03 (0.22)
0.11
0.06 (0.33)
0.04 (0.28)
0.07
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.33)
0.00 (0.28)
0.00
Number of BUN tests ordered
...mean (sd)
0.04 (0.27)
0.04 (0.27)
0.00
0.03 (0.23)
0.02 (0.16)
0.05
0.04 (0.25)
0.03 (0.22)
0.04
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.25)
0.00 (0.22)
0.00
Number of tests for microalbuminuria
...mean (sd)
0.28 (0.78)
0.34 (0.81)
-0.08
0.14 (0.53)
0.16 (0.56)
-0.04
0.21 (0.67)
0.24 (0.69)
-0.04
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.67)
0.00 (0.69)
0.00
Total N distinct ICD9/ICD10 diagnoses at 
the 3rd digit level 
...mean (sd)
11.78 (12.28)
13.43 (11.39)
-0.14
6.46 (8.93)
7.90 (8.45)
-0.17
9.19 (10.78)
10.45 (9.92)
-0.12
...median [IQR]
9.00 [0.00, 18.00]
12.00 [4.00, 19.00]
-0.25
0.00 [0.00, 13.00]
6.00 [0.00, 14.00]
-0.69
4.61 (10.78)
8.77 (9.92)
-0.40
For PS
Hemorrhagic stroke+Other 
cerebrovascular disease+Cerebrovascular 
procedure (for PS); n (%)
1,184 (3.5%)
166 (2.3%)
0.07
615 (1.9%)
81 (1.0%)
0.08
1799 (2.7%)
247 (1.6%)
0.08
Occurrence of creatinine tests ordered (for 
PS); n (%)
1,600 (4.7%)
304 (4.3%)
0.02
1,402 (4.3%)
222 (2.7%)
0.09
3,002 (4.5%)
0,526 (3.4%)
0.06
Occurrence of BUN tests ordered (for PS); n 
(%)
910 (2.7%)
177 (2.5%)
0.01
786 (2.4%)
120 (1.5%)
0.07
1,696 (2.5%)
0,297 (1.9%)
0.04
Occurrence of chronic renal insufficiency 
w/o CKD (for PS) ; n (%)
4,154 (12.1%)
710 (10.0%)
0.07
1,526 (4.7%)
247 (3.0%)
0.09
5,680 (8.5%)
0,957 (6.2%)
0.09
Chronic kidney disease Stage 1-2 (for PS); n 
(%)
1,225 (3.6%)
289 (4.1%)
-0.03
380 (1.2%)
84 (1.0%)
0.02
1605 (2.4%)
373 (2.4%)
0.00
Chronic kidney disease Stage 3-6 (for PS); n 
(%)
5,711 (16.7%)
1,118 (15.8%)
0.02
2,015 (6.2%)
365 (4.4%)
0.08
7,726 (11.6%)
1,483 (9.7%)
0.06
Bladder stones+Kidney stones (for PS); n 
(%)
990 (2.9%)
223 (3.2%)
-0.02
535 (1.6%)
151 (1.8%)
-0.02
1,525 (2.3%)
0,374 (2.4%)
-0.01
Diabetes with peripheral circulatory 
disorders+Gangrene+Osteomyelitis(for PS)  
with ICD10 ; n (%)
2,069 (6.0%)
493 (7.0%)
-0.04
735 (2.3%)
166 (2.0%)
0.02
2,804 (4.2%)
0,659 (4.3%)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Alcohol abuse or dependence+Drug abuse 
or dependence (for PS); n (%)
1,634 (4.8%)
350 (4.9%)
0.00
886 (2.7%)
219 (2.7%)
0.00
2520 (3.8%)
569 (3.7%)
0.01
Diabetes with other ophthalmic 
manifestations+Retinal detachment, 
vitreous hemorrhage, vitrectomy+Retinal 
laser coagulation therapy (for PS); n (%)
338 (1.0%)
73 (1.0%)
0.00
549 (1.7%)
116 (1.4%)
0.02
0,887 (1.3%)
0,189 (1.2%)
0.01
Other atherosclerosis+Cardiac conduction 
disorders+Other CVD (for PS)  ; n (%)
17,674 (51.6%)
3,269 (46.2%)
0.11
12,419 (38.1%)
2,749 (33.3%)
0.10
30,093 (45.0%)
6,018 (39.2%)
0.12
Previous cardiac procedure (CABG or PTCA 
or Stent) + History of CABG or PTCA (for PS) 
; n (%)
27,865 (81.4%)
6,730 (95.1%)
-0.44
25,351 (77.8%)
7,635 (92.4%)
-0.42
53,216 (79.6%)
14,365 (93.6%)
-0.42
Hyperthyroidism + Hypothyroidism + 
Other disorders of thyroid gland (for PS); n 
(%)
6,302 (18.4%)
1,303 (18.4%)
0.00
3,926 (12.1%)
923 (11.2%)
0.03
10,228 (15.3%)
2,226 (14.5%)
0.02
Delirium + Psychosis (for PS); n (%)
1,418 (4.1%)
209 (3.0%)
0.06
690 (2.1%)
100 (1.2%)
0.07
2108 (3.2%)
309 (2.0%)
0.08
Any use of Meglitinides (for PS); n (%)
95 (0.3%)
21 (0.3%)
0.00
112 (0.3%)
31 (0.4%)
-0.02
207 (0.3%)
52 (0.3%)
0.00
Any use of AGIs (for PS); n (%)
35 (0.1%)
7 (0.1%)
0.00
40 (0.1%)
10 (0.1%)
0.00
30,093 (45.0%)
6,018 (39.2%)
0.12
CKD stage 3-6 + dialysis (for PS); n (%)
5,711 (16.7%)
1,118 (15.8%)
0.02
2,015 (6.2%)
365 (4.4%)
0.08
7,726 (11.6%)
1,483 (9.7%)
0.06
Use of thiazide; n (%)
3,544 (10.3%)
675 (9.5%)
0.03
2,983 (9.2%)
654 (7.9%)
0.05
59,039 (88.4%)
13,609 (88.7%)
-0.01
Use of beta blockers; n (%)
30,072 (87.8%)
6,231 (88.0%)
-0.01
28,967 (89.0%)
7,378 (89.3%)
-0.01
18,021 (27.0%)
3,660 (23.9%)
0.07
Use of calcium channel blockers; n (%)
9,975 (29.1%)
1,923 (27.2%)
0.04
8,046 (24.7%)
1,737 (21.0%)
0.09
18,802 (28.1%)
4,954 (32.3%)
-0.09
All antidiabetic medications except 
Insulin; n (%)
10,056 (29.4%)
2,541 (35.9%)
-0.14
8,746 (26.9%)
2,413 (29.2%)
-0.05
6,527 (9.8%)
1,329 (8.7%)
0.04
DM Medications - Insulin ; n (%)
4,442 (13.0%)
1,074 (15.2%)
-0.06
3,925 (12.1%)
1,017 (12.3%)
-0.01
8,367 (12.5%)
2,091 (13.6%)
-0.03
Use of Low Intensity Statins; n (%)
12,706 (37.1%)
2,017 (28.5%)
0.18
12,432 (38.2%)
2,215 (26.8%)
0.25
25138 (37.6%)
4,232 (27.6%)
0.21
Use of High Intensity Statins; n (%)
21,258 (62.1%)
5,363 (75.8%)
-0.30
19,285 (59.2%)
6,350 (76.8%)
-0.38
40543 (60.7%)
11,713 (76.3%)
-0.34
Malignant hypertension; n (%)
2,762 (8.1%)
322 (4.5%)
0.15
17,029 (52.3%)
2,783 (33.7%)
0.38
19791 (29.6%)
3,105 (20.2%)
0.22
Cardiovascular stress test; n (%)
103 (0.3%)
19 (0.3%)
0.00
93 (0.3%)
17 (0.2%)
0.02
0,196 (0.3%)
36 (0.2%)
0.02
Echocardiogram; n (%)
26,110 (76.2%)
5,478 (77.4%)
-0.03
22,761 (69.9%)
5,951 (72.0%)
-0.05
48,871 (73.1%)
11429 (74.5%)
-0.03
Number of BNP tests
...mean (sd)
0.12 (0.48)
0.11 (0.45)
0.02
0.12 (0.43)
0.12 (0.38)
0.00
0.12 (0.46)
0.12 (0.41)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.46)
0.00 (0.41)
0.00
Number of Cardiac biomarkers tests 
(tropnin, CK-MBs, Myoglobin, CPK)
...mean (sd)
0.62 (1.74)
0.59 (1.81)
0.02
0.67 (1.58)
0.66 (1.58)
0.01
0.64 (1.66)
0.63 (1.69)
0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 (1.66)
0.00 (1.69)
0.00
Number of Ambulatory Blood pressure 
monitoring tests
...mean (sd)
0.00 (0.03)
0.00 (0.02)
0.00
0.00 (0.03)
0.00 (0.03)
0.00
0.00 (0.03)
0.00 (0.03)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.03)
0.00 (0.03)
0.00
N of days on antihypertensive medications 
during baseline
...mean (sd)
105.69 (77.47)
100.86 (78.13)
0.06
93.62 (79.43)
83.92 (79.54)
0.12
99.81 (78.43)
91.74 (78.89)
0.10
...median [IQR]
147.00 [1.00, 179.00] 135.00 [1.00, 178.00]
0.15
115.00 [1.00, 
177.00]
78.00 [1.00, 173.00]
0.47
131.40 (78.43)
104.30 (78.89)
0.34
N of days in database anytime prior
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

...mean (sd)
1,835.09 (1,422.04)
1,784.22 (1,449.19)
0.04
2,135.45 (1,386.94)
2,271.61 (1,503.12)
-0.09
1981.48 (1405.04)
2046.75 (1478.48)
-0.05
...median [IQR]
1,433.00 [681.00, 
2,665.00]
1,315.00 [637.75, 
2,606.25]
0.08
1,880.00 [915.00, 
3,295.00]
1,999.00 [950.00, 
3,558.00]
-0.08
1650.86 (1405.04)
1683.44 (1478.48)
-0.02
Mean Copay for per prescription cost 
(charges in U.S. $) (180-1 day prior)
...mean (sd)
23.29 (34.93)
22.94 (32.38)
0.01
18.45 (26.28)
16.63 (21.49)
0.08
20.93 (31.02)
19.54 (27.06)
0.05
...median [IQR]
14.29 [5.85, 29.58]
13.92 [5.00, 29.49]
0.01
12.82 [5.08, 24.33]
10.80 [3.33, 22.51]
0.08
13.57 (31.02)
12.24 (27.06)
0.05
...Missing; n (%)
3,156 (9.2%)
609 (8.6%)
0.02
3,809 (11.7%)
993 (12.0%)
-0.01
6,965 (10.4%)
1602 (10.4%)
0.00
Colonos; n (%)
1,177 (3.4%)
279 (3.9%)
-0.03
991 (3.0%)
292 (3.5%)
-0.03
2,168 (3.2%)
571 (3.7%)
-0.03
Fecal occult blood (FOB) test; n (%)
1,073 (3.1%)
200 (2.8%)
0.02
886 (2.7%)
180 (2.2%)
0.03
1,959 (2.9%)
380 (2.5%)
0.02
Flu vaccine; n (%)
5,381 (15.7%)
1,085 (15.3%)
0.01
3,101 (9.5%)
723 (8.7%)
0.03
8,482 (12.7%)
1808 (11.8%)
0.03
Mammogram; n (%)
2,131 (6.2%)
468 (6.6%)
-0.02
1,397 (4.3%)
322 (3.9%)
0.02
3,528 (5.3%)
790 (5.1%)
0.01
Pap smear; n (%)
485 (1.4%)
114 (1.6%)
-0.02
654 (2.0%)
136 (1.6%)
0.03
1,139 (1.7%)
250 (1.6%)
0.01
Pneumonia vaccine; n (%)
5,203 (15.2%)
1,341 (18.9%)
-0.10
2,015 (6.2%)
721 (8.7%)
-0.10
7,218 (10.8%)
2062 (13.4%)
-0.08
PSA test or Prostate exam for DRE; n (%)
4,519 (13.2%)
1,008 (14.2%)
-0.03
3,148 (9.7%)
932 (11.3%)
-0.05
7,667 (11.5%)
1940 (12.6%)
-0.03
Bone mineral density; n (%)
847 (2.5%)
171 (2.4%)
0.01
371 (1.1%)
87 (1.1%)
0.00
1,218 (1.8%)
258 (1.7%)
0.01
Use of Sympatomimetic agents; n (%)
190 (0.6%)
47 (0.7%)
-0.01
249 (0.8%)
94 (1.1%)
-0.03
0,439 (0.7%)
141 (0.9%)
-0.02
Use of CNS stimulants; n (%)
102 (0.3%)
24 (0.3%)
0.00
162 (0.5%)
48 (0.6%)
-0.01
0,264 (0.4%)
72 (0.5%)
-0.01
Use of estrogens, progestins, androgens; n 
(%)
845 (2.5%)
197 (2.8%)
-0.02
1,332 (4.1%)
328 (4.0%)
0.01
2,177 (3.3%)
525 (3.4%)
-0.01
Use of Angiogenesis inhibitors; n (%)
17 (0.0%)
5 (0.1%)
-0.04
0 (0.0%)
1 (0.0%)
#DIV/0!
0,017 (0.0%)
6 (0.0%)
#DIV/0!
Use of Oral Immunosuppressants; n (%)
52 (0.2%)
15 (0.2%)
0.00
75 (0.2%)
22 (0.3%)
-0.02
0,127 (0.2%)
37 (0.2%)
0.00
Use of fondaparinux or Bivalirudin; n (%)
3 (0.0%)
0 (0.0%)
#DIV/0!
9 (0.0%)
0 (0.0%)
#DIV/0!
0,012 (0.0%)
0 (0.0%)
#DIV/0!
Use of other direct thrombin inhibitors 
(lepirudin, desirudin, argatroban); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0,000 (0.0%)
0 (0.0%)
#DIV/0!
Use of Prasugrel ON CED; n (%)
148 (0.4%)
29 (0.4%)
0.00
155 (0.5%)
34 (0.4%)
0.01
0,303 (0.5%)
63 (0.4%)
0.01
Use of Prasugrel 180 to 1 day prior; n (%)
213 (0.6%)
65 (0.9%)
-0.03
205 (0.6%)
59 (0.7%)
-0.01
0,418 (0.6%)
124 (0.8%)
-0.02
Duration of index hospitalization (i.e. 
anchor hospitalization LOS)
...mean (sd)
4.54 (3.88)
3.98 (3.03)
0.16
3.97 (2.44)
3.38 (1.57)
0.29
4.26 (3.26)
3.66 (2.36)
0.21
...median [IQR]
4.00 [3.00, 5.00]
3.00 [3.00, 4.00]
0.29
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.51 (3.26)
3.00 (2.36)
0.18
Number of D-dimer tests
...mean (sd)
0.04 (0.23)
0.04 (0.23)
0.00
0.05 (0.23)
0.06 (0.26)
-0.04
0.04 (0.23)
0.05 (0.25)
-0.04
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.23)
0.00 (0.25)
0.00
Numbe of CRP, high-sensitivity CRP tests
...mean (sd)
0.06 (0.33)
0.06 (0.30)
0.00
0.04 (0.27)
0.04 (0.27)
0.00
0.05 (0.30)
0.05 (0.28)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.30)
0.00 (0.28)
0.00
Number of PT or aPTTt tests
...mean (sd)
0.59 (1.97)
0.40 (1.37)
0.11
0.48 (1.37)
0.37 (0.98)
0.09
0.54 (1.70)
0.38 (1.18)
0.11
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (1.70)
0.00 (1.18)
0.00
Number of Bleeding time tests
...mean (sd)
0.00 (0.02)
0.00 (0.02)
0.00
0.00 (0.02)
0.00 (0.02)
0.00
0.00 (0.02)
0.00 (0.02)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.02)
0.00 (0.02)
0.00
HAS-BLED Score (ICD-9 and ICD-10), 180 
days
...mean (sd)
4.05 (0.76)
3.90 (0.75)
0.20
3.57 (0.66)
3.36 (0.59)
0.34
3.82 (0.71)
3.61 (0.67)
0.30
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

...median [IQR]
4.00 [4.00, 4.00]
4.00 [3.00, 4.00]
0.00
4.00 [3.00, 4.00]
3.00 [3.00, 4.00]
1.60
4.00 (0.71)
3.46 (0.67)
0.78
Drug eluting stent; n (%)
8,430 (24.6%)
1,218 (17.2%)
0.18
10,014 (30.8%)
2,371 (28.7%)
0.05
18,444 (27.6%)
3589 (23.4%)
0.10
Bare metal stent; n (%)
18,447 (53.9%)
5,947 (84.0%)
-0.69
15,203 (46.7%)
7,011 (84.8%)
-0.88
33,650 (50.4%)
12958 (84.5%)
-0.78
Use of CYP inhibitors; n (%)
7,802 (22.8%)
1,443 (20.4%)
0.06
6,227 (19.1%)
1,374 (16.6%)
0.07
14,029 (21.0%)
2817 (18.4%)
0.07
Use of CYP inducers; n (%)
41 (0.1%)
7 (0.1%)
0.00
64 (0.2%)
9 (0.1%)
0.03
0,105 (0.2%)
16 (0.1%)
0.03
Commercial vs Medicare Advantage- 
Business Type Code - CORRECT ONE - 
TRUVEN
...Commercial; n (%)
9,219 (26.9%)
2,194 (31.0%)
-0.09
15,361 (47.2%)
2,555 (30.9%)
0.34
24,580 (36.8%)
4749 (31.0%)
0.12
...Medicare Advantage; n (%)
25,032 (73.1%)
4,884 (69.0%)
0.09
17,204 (52.8%)
5,709 (69.1%)
-0.34
42,236 (63.2%)
10593 (69.0%)
-0.12
Commercial vs Medicare Advantage- 
Business Type Code
...COM = COMMERCIAL; n (%)
9,219 (26.9%)
2,194 (31.0%)
-0.09
-
-
#VALUE!
9,219 (26.9%)
2,194 (31.0%)
-0.09
...MCR = MEDICARE; n (%)
25,032 (73.1%)
4,884 (69.0%)
0.09
-
-
#VALUE!
25,032 (73.1%)
4,884 (69.0%)
0.09
...MCD = MEDICAID; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...NONE = NO BUSINESS LINE CODE (added 
in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
Commercial vs Medicare Advantage- Data 
Type
...1 - Fee For Service; n (%)
-
-
#VALUE!
15,223 (46.7%)
5,158 (62.4%)
-0.32
15,223 (46.7%)
5,158 (62.4%)
-0.32
...2 - Encounter; n (%)
-
-
#VALUE!
1,981 (6.1%)
551 (6.7%)
-0.02
1,981 (6.1%)
551 (6.7%)
-0.02
...3 - Medicare; n (%)
-
-
#VALUE!
13,443 (41.3%)
2,290 (27.7%)
0.29
13,443 (41.3%)
2,290 (27.7%)
0.29
...4 - Medicare Encounter; n (%)
-
-
#VALUE!
1,918 (5.9%)
265 (3.2%)
0.13
1,918 (5.9%)
265 (3.2%)
0.13
Metropolitan Statistical Area - Urban (any 
MSA) vs Rural (non-MSA)
...Urban; n (%)
-
-
#VALUE!
23,495 (72.1%)
5,859 (70.9%)
0.03
23,495 (72.1%)
5,859 (70.9%)
0.03
...Rural; n (%)
-
-
#VALUE!
1,316 (4.0%)
628 (7.6%)
-0.15
1,316 (4.0%)
628 (7.6%)
-0.15
...Unknown/Missing; n (%)
-
-
#VALUE!
7,754 (23.8%)
1,777 (21.5%)
0.05497
7,754 (23.8%)
1,777 (21.5%)
0.05
N of Generic name drugs
...mean (sd)
17.06 (13.53)
15.92 (13.38)
0.08
13.50 (10.40)
12.08 (9.64)
0.14
15.32 (12.11)
13.85 (11.52)
0.12
...median [IQR]
14.00 [8.00, 22.00]
12.00 [7.00, 21.00]
0.15
11.00 [6.00, 18.00]
10.00 [5.00, 16.00]
0.10
12.54 (12.11)
10.92 (11.52)
0.14
N of Brand name drugs
...mean (sd)
3.13 (4.46)
3.86 (4.39)
-0.16
3.48 (4.24)
3.82 (3.89)
-0.08
3.30 (4.35)
3.84 (4.13)
-0.13
...median [IQR]
1.00 [0.00, 4.00]
2.00 [1.00, 5.00]
-0.226
2.00 [1.00, 5.00]
2.00 [1.00, 5.00]
0
1.49 (4.35)
2.00 (4.13)
-0.12
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Variable
Clopidogrel 75mg
Ticagrelor 90mg
St. Diff.
Clopidogrel 75mg
Ticagrelor 90mg
St. Diff.
Clopidogrel 75mg
Ticagrelor 90mg
St. Diff.
Number of patients
                                 6,697                                  6,697 
                              7,283                               7,283 
                             13,980                              13,980 
Age
...mean (sd)
68.19 (10.96)
68.38 (10.66)
-0.02
62.57 (11.12)
62.72 (10.33)
-0.01
65.26 (11.04)
65.43 (10.49)
-0.02
...median [IQR]
69.00 [61.00, 76.00] 69.00 [62.00, 76.00]
0.00
62.00 [56.00, 
69 00]
62.00 [57.00, 
68 00]
0.00
65.35 (11.04)
65.35 (10.49)
0.00
Age categories
...18 - 54; n (%)
761 (11.4%)
716 (10.7%)
0.02
1,548 (21.3%)
1,372 (18.8%)
0.06
2,309 (16.5%)
2,088 (14.9%)
0.04
...55 - 64; n (%)
1,531 (22.9%)
1,473 (22.0%)
0.02
3,310 (45.4%)
3,451 (47.4%)
-0.04
4,841 (34.6%)
4,924 (35.2%)
-0.01
...65 - 74; n (%)
2,461 (36.7%)
2,515 (37.6%)
-0.02
1,339 (18.4%)
1,446 (19.9%)
-0.04
3,800 (27.2%)
3,961 (28.3%)
-0.02
...>= 75; n (%)
1,944 (29.0%)
1,993 (29.8%)
-0.02
1,086 (14.9%)
1,014 (13.9%)
0.03
3,030 (21.7%)
3,007 (21.5%)
0.00
Gender
...Males; n (%)
4,290 (64.1%)
4,277 (63.9%)
0.00
5,161 (70.9%)
5,145 (70.6%)
0.01
9,451 (67.6%)
9,422 (67.4%)
0.00
...Females; n (%)
2,407 (35.9%)
2,420 (36.1%)
0.00
2,122 (29.1%)
2,138 (29.4%)
-0.01
4,529 (32.4%)
4,558 (32.6%)
0.00
Region
...Northeast; n (%)
777 (11.6%)
772 (11.5%)
0.00
1,356 (18.6%)
1,386 (19.0%)
-0.01
2,133 (15.3%)
2,158 (15.4%)
0.00
...South; n (%)
3,136 (46.8%)
3,102 (46.3%)
0.01
2,027 (27.8%)
2,009 (27.6%)
0.00
5,163 (36.9%)
5,111 (36.6%)
0.01
...Midwest; n (%)
1,524 (22.8%)
1,566 (23.4%)
-0.01
3,064 (42.1%)
3,047 (41.8%)
0.01
4,588 (32.8%)
4,613 (33.0%)
0.00
...West; n (%)
1,260 (18.8%)
1,257 (18.8%)
0.00
796 (10.9%)
803 (11.0%)
0.00
2,056 (14.7%)
2,060 (14.7%)
0.00
...Unknown+missing; n (%)
N/A
N/A
#VALUE!
40 (0.5%)
38 (0.5%)
0.00
40 (0.3%)
38 (0.3%)
0.00
CV Covariates
Ischemic heart disease; n (%)
6,697 (100.0%)
6,697 (100.0%)
#DIV/0!
7,283 (100.0%)
7,283 (100.0%)
#DIV/0!
13,980 (100.0%)
13,980 (100.0%)
#DIV/0!
Acute MI; n (%)
6,135 (91.6%)
6,128 (91.5%)
0.00
6,879 (94.5%)
6,876 (94.4%)
0.00
13014 (93.1%)
13004 (93.0%)
0.00
ACS/unstable angina; n (%)
2,839 (42.4%)
2,840 (42.4%)
0.00
2,601 (35.7%)
2,637 (36.2%)
-0.01
5440 (38.9%)
5477 (39.2%)
-0.01
Old MI; n (%)
1,126 (16.8%)
1,128 (16.8%)
0.00
684 (9.4%)
652 (9.0%)
0.01
1810 (12.9%)
1780 (12.7%)
0.01
Stable angina; n (%)
1,622 (24.2%)
1,691 (25.3%)
-0.03
1,196 (16.4%)
1,199 (16.5%)
0.00
2,818 (20.2%)
2,890 (20.7%)
-0.01
Coronary atherosclerosis and other forms of 
chronic ischemic heart disease; n (%)
6,437 (96.1%)
6,433 (96.1%)
0.00
6,745 (92.6%)
6,733 (92.4%)
0.01
13,182 (94.3%)
13,166 (94.2%)
0.00
Other atherosclerosis with ICD10  ; n (%)
86 (1.3%)
81 (1.2%)
0.01
98 (1.3%)
85 (1.2%)
0.01
184 (1.3%)
166 (1.2%)
0.01
Previous cardiac procedure (CABG or PTCA or 
Stent) ; n (%)
6,024 (90.0%)
6,183 (92.3%)
-0.08
6,519 (89.5%)
6,549 (89.9%)
-0.01
12543 (89.7%)
12732 (91.1%)
-0.05
History of CABG or PTCA; n (%)
2,490 (37.2%)
2,351 (35.1%)
0.04
1,494 (20.5%)
1,309 (18.0%)
0.06
3,984 (28.5%)
3,660 (26.2%)
0.05
Any stroke; n (%)
622 (9.3%)
601 (9.0%)
0.01
406 (5.6%)
416 (5.7%)
0.00
1,028 (7.4%)
1,017 (7.3%)
0.00
Ischemic stroke (w and w/o mention of cerebral 
infarction); n (%)
616 (9.2%)
598 (8.9%)
0.01
406 (5.6%)
416 (5.7%)
0.00
1,022 (7.3%)
1,014 (7.3%)
0.00
Hemorrhagic stroke; n (%)
13 (0.2%)
7 (0.1%)
0.03
0 (0.0%)
0 (0.0%)
#DIV/0!
13 (0.1%)
7 (0.1%)
0.00
TIA; n (%)
120 (1.8%)
125 (1.9%)
-0.01
83 (1.1%)
77 (1.1%)
0.00
203 (1.5%)
202 (1.4%)
0.01
Other cerebrovascular disease; n (%)
143 (2.1%)
151 (2.3%)
-0.01
72 (1.0%)
73 (1.0%)
0.00
215 (1.5%)
224 (1.6%)
-0.01
Late effects of cerebrovascular disease; n (%)
134 (2.0%)
135 (2.0%)
0.00
51 (0.7%)
50 (0.7%)
0.00
185 (1.3%)
185 (1.3%)
0.00
Cerebrovascular procedure; n (%)
8 (0.1%)
8 (0.1%)
0.00
7 (0.1%)
4 (0.1%)
0.00
15 (0.1%)
12 (0.1%)
0.00
Heart failure (CHF); n (%)
1,722 (25.7%)
1,720 (25.7%)
0.00
1,134 (15.6%)
1,134 (15.6%)
0.00
2,856 (20.4%)
2,854 (20.4%)
0.00
Peripheral Vascular Disease (PVD) or PVD 
Surgery ; n (%)
874 (13.1%)
843 (12.6%)
0.01
397 (5.5%)
394 (5.4%)
0.00
1,271 (9.1%)
1,237 (8.8%)
0.01
Atrial fibrillation; n (%)
815 (12.2%)
823 (12.3%)
0.00
598 (8.2%)
561 (7.7%)
0.02
1,413 (10.1%)
1,384 (9.9%)
0.01
Other cardiac dysrhythmia; n (%)
2,463 (36.8%)
2,524 (37.7%)
-0.02
2,216 (30.4%)
2,204 (30.3%)
0.00
4,679 (33.5%)
4,728 (33.8%)
-0.01
Optum
PS-matched
Truven
POOLED
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Cardiac conduction disorders; n (%)
1,075 (16.1%)
1,041 (15.5%)
0.02
749 (10.3%)
748 (10.3%)
0.00
1824 (13.0%)
1789 (12.8%)
0.01
Other CVD; n (%)
2,475 (37.0%)
2,563 (38.3%)
-0.03
1,945 (26.7%)
1,998 (27.4%)
-0.02
4,420 (31.6%)
4,561 (32.6%)
-0.02
Diabetes-related complications
Diabetic retinopathy; n (%)
267 (4.0%)
253 (3.8%)
0.01
144 (2.0%)
132 (1.8%)
0.01
0,411 (2.9%)
0,385 (2.8%)
0.01
Diabetes with other ophthalmic 
manifestations; n (%)
25 (0.4%)
36 (0.5%)
-0.01
67 (0.9%)
63 (0.9%)
0.00
0,092 (0.7%)
0,099 (0.7%)
0.00
Retinal detachment, vitreous hemorrhage, 
vitrectomy; n (%)
28 (0.4%)
15 (0.2%)
0.04
21 (0.3%)
21 (0.3%)
0.00
49 (0.4%)
36 (0.3%)
0.02
Retinal laser coagulation therapy; n (%)
27 (0.4%)
28 (0.4%)
0.00
34 (0.5%)
30 (0.4%)
0.01
61 (0.4%)
58 (0.4%)
0.00
Occurrence of Diabetic Neuropathy  ; n (%)
871 (13.0%)
833 (12.4%)
0.02
389 (5.3%)
371 (5.1%)
0.01
1,260 (9.0%)
1,204 (8.6%)
0.01
Occurrence of diabetic nephropathy  with 
ICD10 ; n (%)
814 (12.2%)
805 (12.0%)
0.01
220 (3.0%)
224 (3.1%)
-0.01
1,034 (7.4%)
1,029 (7.4%)
0.00
Hypoglycemia ; n (%)
56 (0.8%)
40 (0.6%)
0.02
97 (1.3%)
91 (1.2%)
0.01
0,153 (1.1%)
0,131 (0.9%)
0.02
Hyperglycemia; n (%)
600 (9.0%)
604 (9.0%)
0.00
444 (6.1%)
442 (6.1%)
0.00
1,044 (7.5%)
1,046 (7.5%)
0.00
Disorders of fluid electrolyte and acid-base 
balance; n (%)
1,318 (19.7%)
1,332 (19.9%)
-0.01
681 (9.4%)
709 (9.7%)
-0.01
1,999 (14.3%)
2,041 (14.6%)
-0.01
Diabetic ketoacidosis; n (%)
43 (0.6%)
35 (0.5%)
0.01
45 (0.6%)
43 (0.6%)
0.00
88 (0.6%)
78 (0.6%)
0.00
Hyperosmolar hyperglycemic nonketotic 
syndrome (HONK); n (%)
31 (0.5%)
32 (0.5%)
0.00
12 (0.2%)
12 (0.2%)
0.00
43 (0.3%)
44 (0.3%)
0.00
Diabetes with peripheral circulatory disorders 
with ICD-10  ; n (%)
444 (6.6%)
441 (6.6%)
0.00
132 (1.8%)
127 (1.7%)
0.01
0,576 (4.1%)
0,568 (4.1%)
0.00
Diabetic Foot; n (%)
105 (1.6%)
101 (1.5%)
0.01
67 (0.9%)
67 (0.9%)
0.00
172 (1.2%)
168 (1.2%)
0.00
Gangrene ; n (%)
10 (0.1%)
9 (0.1%)
0.00
8 (0.1%)
3 (0.0%)
0.04
18 (0.1%)
12 (0.1%)
0.00
Lower extremity amputation; n (%)
50 (0.7%)
45 (0.7%)
0.00
12 (0.2%)
14 (0.2%)
0.00
62 (0.4%)
59 (0.4%)
0.00
Osteomyelitis; n (%)
23 (0.3%)
29 (0.4%)
-0.02
13 (0.2%)
19 (0.3%)
-0.02
36 (0.3%)
48 (0.3%)
0.00
Skin infections ; n (%)
309 (4.6%)
313 (4.7%)
0.00
252 (3.5%)
253 (3.5%)
0.00
0,561 (4.0%)
0,566 (4.0%)
0.00
Erectile dysfunction; n (%)
208 (3.1%)
216 (3.2%)
-0.01
182 (2.5%)
179 (2.5%)
0.00
0,390 (2.8%)
0,395 (2.8%)
0.00
Diabetes with unspecified complication; n (%)
373 (5.6%)
364 (5.4%)
0.01
225 (3.1%)
216 (3.0%)
0.01
0,598 (4.3%)
0,580 (4.1%)
0.01
Diabetes mellitus without mention of 
complications; n (%)
3,495 (52.2%)
3,487 (52.1%)
0.00
2,994 (41.1%)
2,965 (40.7%)
0.01
6,489 (46.4%)
6,452 (46.2%)
0.00
Hypertension: 1 inpatient or 2 outpatient 
claims within 365 days; n (%)
5,783 (86.4%)
5,821 (86.9%)
-0.01
5,612 (77.1%)
5,617 (77.1%)
0.00
11,395 (81.5%)
11,438 (81.8%)
-0.01
Hyperlipidemia ; n (%)
5,592 (83.5%)
5,633 (84.1%)
-0.02
5,162 (70.9%)
5,159 (70.8%)
0.00
10,754 (76.9%)
10,792 (77.2%)
-0.01
Edema; n (%)
447 (6.7%)
442 (6.6%)
0.00
214 (2.9%)
220 (3.0%)
-0.01
0,661 (4.7%)
0,662 (4.7%)
0.00
Renal Dysfunction (non-diabetic) ; n (%)
2,007 (30.0%)
2,049 (30.6%)
-0.01
999 (13.7%)
969 (13.3%)
0.01
3,006 (21.5%)
3,018 (21.6%)
0.00
Occurrence of acute renal disease ; n (%)
928 (13.9%)
919 (13.7%)
0.01
419 (5.8%)
425 (5.8%)
0.00
1347 (9.6%)
1344 (9.6%)
0.00
Occurrence of chronic renal insufficiency; n (%)
1,520 (22.7%)
1,503 (22.4%)
0.01
534 (7.3%)
520 (7.1%)
0.01
2,054 (14.7%)
2,023 (14.5%)
0.01
Chronic kidney disease ; n (%)
1,486 (22.2%)
1,464 (21.9%)
0.01
516 (7.1%)
494 (6.8%)
0.01
2,002 (14.3%)
1,958 (14.0%)
0.01
CKD Stage 3-4; n (%)
1,056 (15.8%)
1,045 (15.6%)
0.01
336 (4.6%)
330 (4.5%)
0.00
1,392 (10.0%)
1,375 (9.8%)
0.01
Occurrence of hypertensive nephropathy; n (%)
1,199 (17.9%)
1,177 (17.6%)
0.01
362 (5.0%)
363 (5.0%)
0.00
1561 (11.2%)
1540 (11.0%)
0.01
Occurrence of miscellaneous renal insufficiency 
; n (%)
580 (8.7%)
598 (8.9%)
-0.01
306 (4.2%)
307 (4.2%)
0.00
0,886 (6.3%)
0,905 (6.5%)
-0.01
Glaucoma or cataracts ; n (%)
1,046 (15.6%)
1,061 (15.8%)
-0.01
817 (11.2%)
798 (11.0%)
0.01
1,863 (13.3%)
1,859 (13.3%)
0.00
Cellulitis or abscess of toe; n (%)
94 (1.4%)
82 (1.2%)
0.02
38 (0.5%)
47 (0.6%)
-0.01
132 (0.9%)
129 (0.9%)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Foot ulcer; n (%)
107 (1.6%)
104 (1.6%)
0.00
63 (0.9%)
67 (0.9%)
0.00
170 (1.2%)
171 (1.2%)
0.00
Bladder stones; n (%)
13 (0.2%)
8 (0.1%)
0.03
9 (0.1%)
8 (0.1%)
0.00
22 (0.2%)
16 (0.1%)
0.03
Kidney stones; n (%)
218 (3.3%)
207 (3.1%)
0.01
127 (1.7%)
120 (1.6%)
0.01
0,345 (2.5%)
0,327 (2.3%)
0.01
Urinary tract infections (UTIs); n (%)
588 (8.8%)
597 (8.9%)
0.00
291 (4.0%)
280 (3.8%)
0.01
0,879 (6.3%)
0,877 (6.3%)
0.00
Dipstick urinalysis; n (%)
1,825 (27.3%)
1,872 (28.0%)
-0.02
1,486 (20.4%)
1,441 (19.8%)
0.01
3,311 (23.7%)
3,313 (23.7%)
0.00
Non-dipstick urinalysis; n (%)
1,275 (19.0%)
1,303 (19.5%)
-0.01
748 (10.3%)
734 (10.1%)
0.01
2,023 (14.5%)
2,037 (14.6%)
0.00
Urine function test; n (%)
148 (2.2%)
152 (2.3%)
-0.01
116 (1.6%)
132 (1.8%)
-0.02
0,264 (1.9%)
0,284 (2.0%)
-0.01
Cytology; n (%)
69 (1.0%)
83 (1.2%)
-0.02
25 (0.3%)
32 (0.4%)
-0.02
94 (0.7%)
115 (0.8%)
-0.01
Cystos; n (%)
102 (1.5%)
103 (1.5%)
0.00
57 (0.8%)
36 (0.5%)
0.04
159 (1.1%)
139 (1.0%)
0.01
Other Covariates
Liver disease; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0,000 (0.0%)
0,000 (0.0%)
#DIV/0!
Osteoarthritis; n (%)
1,393 (20.8%)
1,383 (20.7%)
0.00
848 (11.6%)
881 (12.1%)
-0.02
2,241 (16.0%)
2,264 (16.2%)
-0.01
Other arthritis, arthropathies and 
musculoskeletal pain; n (%)
2,587 (38.6%)
2,593 (38.7%)
0.00
2,193 (30.1%)
2,215 (30.4%)
-0.01
4,780 (34.2%)
4,808 (34.4%)
0.00
Dorsopathies; n (%)
1,774 (26.5%)
1,745 (26.1%)
0.01
1,480 (20.3%)
1,469 (20.2%)
0.00
3,254 (23.3%)
3,214 (23.0%)
0.01
Fractures; n (%)
206 (3.1%)
195 (2.9%)
0.01
132 (1.8%)
137 (1.9%)
-0.01
0,338 (2.4%)
0,332 (2.4%)
0.00
Falls ; n (%)
255 (3.8%)
255 (3.8%)
0.00
73 (1.0%)
66 (0.9%)
0.01
328 (2.3%)
321 (2.3%)
0.00
Osteoporosis; n (%)
310 (4.6%)
314 (4.7%)
0.00
155 (2.1%)
156 (2.1%)
0.00
0,465 (3.3%)
0,470 (3.4%)
-0.01
Hyperthyroidism; n (%)
33 (0.5%)
45 (0.7%)
-0.03
22 (0.3%)
22 (0.3%)
0.00
55 (0.4%)
67 (0.5%)
-0.01
Hypothyroidism ; n (%)
1,142 (17.1%)
1,098 (16.4%)
0.02
706 (9.7%)
734 (10.1%)
-0.01
1,848 (13.2%)
1,832 (13.1%)
0.00
Other disorders of thyroid gland ; n (%)
203 (3.0%)
236 (3.5%)
-0.03
174 (2.4%)
164 (2.3%)
0.01
0,377 (2.7%)
0,400 (2.9%)
-0.01
Depression; n (%)
779 (11.6%)
782 (11.7%)
0.00
449 (6.2%)
458 (6.3%)
0.00
1,228 (8.8%)
1,240 (8.9%)
0.00
Anxiety; n (%)
947 (14.1%)
939 (14.0%)
0.00
586 (8.0%)
601 (8.3%)
-0.01
1,533 (11.0%)
1,540 (11.0%)
0.00
SleepDisorder; n (%)
301 (4.5%)
316 (4.7%)
-0.01
466 (6.4%)
439 (6.0%)
0.02
0,767 (5.5%)
0,755 (5.4%)
0.00
Dementia; n (%)
292 (4.4%)
303 (4.5%)
0.00
112 (1.5%)
119 (1.6%)
-0.01
404 (2.9%)
422 (3.0%)
-0.01
Delirium; n (%)
162 (2.4%)
155 (2.3%)
0.01
65 (0.9%)
67 (0.9%)
0.00
227 (1.6%)
222 (1.6%)
0.00
Psychosis; n (%)
67 (1.0%)
61 (0.9%)
0.01
32 (0.4%)
34 (0.5%)
-0.01
99 (0.7%)
95 (0.7%)
0.00
Obesity; n (%)
1,796 (26.8%)
1,832 (27.4%)
-0.01
1,445 (19.8%)
1,357 (18.6%)
0.03
3,241 (23.2%)
3,189 (22.8%)
0.01
Overweight; n (%)
484 (7.2%)
489 (7.3%)
0.00
218 (3.0%)
217 (3.0%)
0.00
0,702 (5.0%)
0,706 (5.1%)
0.00
Smoking; n (%)
3,128 (46.7%)
3,124 (46.6%)
0.00
2,083 (28.6%)
2,118 (29.1%)
-0.01
5,211 (37.3%)
5,242 (37.5%)
0.00
Alcohol abuse or dependence; n (%)
152 (2.3%)
159 (2.4%)
-0.01
108 (1.5%)
114 (1.6%)
-0.01
260 (1.9%)
273 (2.0%)
-0.01
Drug abuse or dependence; n (%)
195 (2.9%)
188 (2.8%)
0.01
91 (1.2%)
94 (1.3%)
-0.01
286 (2.0%)
282 (2.0%)
0.00
COPD; n (%)
1,228 (18.3%)
1,230 (18.4%)
0.00
671 (9.2%)
640 (8.8%)
0.01
1,899 (13.6%)
1,870 (13.4%)
0.01
Asthma; n (%)
484 (7.2%)
494 (7.4%)
-0.01
363 (5.0%)
369 (5.1%)
0.00
0,847 (6.1%)
0,863 (6.2%)
0.00
Obstructive sleep apnea; n (%)
770 (11.5%)
783 (11.7%)
-0.01
630 (8.7%)
612 (8.4%)
0.01
1,400 (10.0%)
1,395 (10.0%)
0.00
Pneumonia; n (%)
425 (6.3%)
456 (6.8%)
-0.02
198 (2.7%)
219 (3.0%)
-0.02
0,623 (4.5%)
0,675 (4.8%)
-0.01
Imaging; n (%)
211 (3.2%)
203 (3.0%)
0.01
80 (1.1%)
101 (1.4%)
-0.03
291 (2.1%)
304 (2.2%)
-0.01
Other Medications
Use of ACE inhibitors; n (%)
3,488 (52.1%)
3,508 (52.4%)
-0.01
4,129 (56.7%)
4,130 (56.7%)
0.00
7,617 (54.5%)
7,638 (54.6%)
0.00
Use of ARBs; n (%)
1,623 (24.2%)
1,647 (24.6%)
-0.01
1,544 (21.2%)
1,551 (21.3%)
0.00
3,167 (22.7%)
3,198 (22.9%)
0.00
Use of Loop Diuretics - ; n (%)
1,034 (15.4%)
1,025 (15.3%)
0.00
580 (8.0%)
588 (8.1%)
0.00
1,614 (11.5%)
1,613 (11.5%)
0.00
Use of other diuretics- ; n (%)
318 (4.7%)
327 (4.9%)
-0.01
322 (4.4%)
302 (4.1%)
0.01
0,640 (4.6%)
0,629 (4.5%)
0.00
Use of nitrates-; n (%)
2,918 (43.6%)
2,928 (43.7%)
0.00
3,267 (44.9%)
3,251 (44.6%)
0.01
6,185 (44.2%)
6,179 (44.2%)
0.00
Use of other hypertension drugs; n (%)
518 (7.7%)
509 (7.6%)
0.00
352 (4.8%)
353 (4.8%)
0.00
0,870 (6.2%)
0,862 (6.2%)
0.00
Use of digoxin- ; n (%)
72 (1.1%)
71 (1.1%)
0.00
70 (1.0%)
62 (0.9%)
0.01
142 (1.0%)
133 (1.0%)
0.00
Use of Anti-arrhythmics; n (%)
178 (2.7%)
204 (3.0%)
-0.02
159 (2.2%)
154 (2.1%)
0.01
337 (2.4%)
358 (2.6%)
-0.01
Use of COPD/asthma meds- ; n (%)
1,024 (15.3%)
1,023 (15.3%)
0.00
885 (12.2%)
894 (12.3%)
0.00
1,909 (13.7%)
1,917 (13.7%)
0.00
Use of statins; n (%)
6,026 (90.0%)
6,037 (90.1%)
0.00
6,668 (91.6%)
6,661 (91.5%)
0.00
12,694 (90.8%)
12,698 (90.8%)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Use of other lipid-lowering drugs; n (%)
504 (7.5%)
511 (7.6%)
0.00
660 (9.1%)
658 (9.0%)
0.00
1,164 (8.3%)
1,169 (8.4%)
0.00
Use of oral anticoagulants (Dabigatran, 
Rivaroxaban, Apixaban, Warfarin); n (%)
367 (5.5%)
349 (5.2%)
0.01
346 (4.8%)
312 (4.3%)
0.02
0,713 (5.1%)
0,661 (4.7%)
0.02
Use of heparin and other low-molecular weight 
heparins; n (%)
37 (0.6%)
41 (0.6%)
0.00
0 (0.0%)
0 (0.0%)
#DIV/0!
37 (0.3%)
41 (0.3%)
0.00
Use of NSAIDs; n (%)
997 (14.9%)
1,014 (15.1%)
-0.01
1,127 (15.5%)
1,115 (15.3%)
0.01
2,124 (15.2%)
2,129 (15.2%)
0.00
Use of oral corticosteroids; n (%)
1,231 (18.4%)
1,215 (18.1%)
0.01
1,145 (15.7%)
1,119 (15.4%)
0.01
2,376 (17.0%)
2,334 (16.7%)
0.01
Use of bisphosphonate (); n (%)
113 (1.7%)
108 (1.6%)
0.01
69 (0.9%)
64 (0.9%)
0.00
182 (1.3%)
172 (1.2%)
0.01
Use of opioids- ; n (%)
1,663 (24.8%)
1,668 (24.9%)
0.00
1,603 (22.0%)
1,582 (21.7%)
0.01
3,266 (23.4%)
3,250 (23.2%)
0.00
Use of antidepressants; n (%)
1,356 (20.2%)
1,338 (20.0%)
0.00
1,158 (15.9%)
1,165 (16.0%)
0.00
2,514 (18.0%)
2,503 (17.9%)
0.00
Use of antipsychotics; n (%)
128 (1.9%)
139 (2.1%)
-0.01
63 (0.9%)
68 (0.9%)
0.00
0,191 (1.4%)
0,207 (1.5%)
-0.01
Use of anticonvulsants; n (%)
975 (14.6%)
907 (13.5%)
0.03
612 (8.4%)
577 (7.9%)
0.02
1,587 (11.4%)
1,484 (10.6%)
0.03
Use of lithium- ; n (%)
10 (0.1%)
11 (0.2%)
-0.03
6 (0.1%)
6 (0.1%)
0.00
16 (0.1%)
17 (0.1%)
0.00
Use of Benzos- ; n (%)
792 (11.8%)
764 (11.4%)
0.01
761 (10.4%)
742 (10.2%)
0.01
1,553 (11.1%)
1,506 (10.8%)
0.01
Use of anxiolytics/hypnotics- ; n (%)
310 (4.6%)
306 (4.6%)
0.00
399 (5.5%)
381 (5.2%)
0.01
0,709 (5.1%)
0,687 (4.9%)
0.01
Use of dementia meds- ; n (%)
118 (1.8%)
121 (1.8%)
0.00
60 (0.8%)
59 (0.8%)
0.00
178 (1.3%)
180 (1.3%)
0.00
Use of antiparkinsonian meds- ; n (%)
154 (2.3%)
147 (2.2%)
0.01
100 (1.4%)
103 (1.4%)
0.00
0,254 (1.8%)
0,250 (1.8%)
0.00
Entresto (sacubitril/valsartan); n (%)
15 (0.2%)
16 (0.2%)
0.00
6 (0.1%)
3 (0.0%)
0.04
21 (0.2%)
19 (0.1%)
0.03
Labs
Lab values- HbA1c (%) ; n (%)
1,404 (21.0%)
1,381 (20.6%)
0.01
128 (1.8%)
103 (1.4%)
0.03
1,532 (11.0%)
1,484 (10.6%)
0.01
Lab values- HbA1c (%) (within 3 months) ; n (%)
920 (13.7%)
888 (13.3%)
0.01
75 (1.0%)
74 (1.0%)
0.00
0,995 (7.1%)
0,962 (6.9%)
0.01
Lab values- HbA1c (%) (within 6 months) ; n (%)
1,404 (21.0%)
1,381 (20.6%)
0.01
128 (1.8%)
103 (1.4%)
0.03
1,532 (11.0%)
1,484 (10.6%)
0.01
Lab values- BNP; n (%)
87 (1.3%)
74 (1.1%)
0.02
10 (0.1%)
2 (0.0%)
0.04
97 (0.7%)
76 (0.5%)
0.03
Lab values- BNP (within 3 months); n (%)
72 (1.1%)
53 (0.8%)
0.03
7 (0.1%)
1 (0.0%)
0.04
79 (0.6%)
54 (0.4%)
0.03
Lab values- BNP (within 6 months); n (%)
87 (1.3%)
74 (1.1%)
0.02
10 (0.1%)
2 (0.0%)
0.04
97 (0.7%)
76 (0.5%)
0.03
Lab values- BUN (mg/dl); n (%)
1,874 (28.0%)
1,893 (28.3%)
-0.01
126 (1.7%)
116 (1.6%)
0.01
2,000 (14.3%)
2,009 (14.4%)
0.00
Lab values- BUN (mg/dl) (within 3 months); n 
(%)
1,255 (18.7%)
1,255 (18.7%)
0.00
75 (1.0%)
72 (1.0%)
0.00
1,330 (9.5%)
1,327 (9.5%)
0.00
Lab values- BUN (mg/dl) (within 6 months); n 
(%)
1,874 (28.0%)
1,893 (28.3%)
-0.01
126 (1.7%)
116 (1.6%)
0.01
2,000 (14.3%)
2,009 (14.4%)
0.00
Lab values- Creatinine (mg/dl) ; n (%)
1,936 (28.9%)
1,945 (29.0%)
0.00
140 (1.9%)
125 (1.7%)
0.02
2,076 (14.8%)
2,070 (14.8%)
0.00
Lab values- Creatinine (mg/dl) (within 3 
months) ; n (%)
1,301 (19.4%)
1,295 (19.3%)
0.00
83 (1.1%)
81 (1.1%)
0.00
1,384 (9.9%)
1,376 (9.8%)
0.00
Lab values- Creatinine (mg/dl) (within 6 
months) ; n (%)
1,936 (28.9%)
1,945 (29.0%)
0.00
140 (1.9%)
125 (1.7%)
0.02
2,076 (14.8%)
2,070 (14.8%)
0.00
Lab values- HDL level (mg/dl); n (%)
1,456 (21.7%)
1,486 (22.2%)
-0.01
118 (1.6%)
96 (1.3%)
0.03
1,574 (11.3%)
1,582 (11.3%)
0.00
Lab values- HDL level (mg/dl) (within 3 months); 
n (%)
890 (13.3%)
898 (13.4%)
0.00
58 (0.8%)
55 (0.8%)
0.00
0,948 (6.8%)
0,953 (6.8%)
0.00
Lab values- HDL level (mg/dl) (within 6 months); 
n (%)
1,456 (21.7%)
1,486 (22.2%)
-0.01
118 (1.6%)
96 (1.3%)
0.03
1,574 (11.3%)
1,582 (11.3%)
0.00
Lab values- LDL level (mg/dl) ; n (%)
1,496 (22.3%)
1,555 (23.2%)
-0.02
130 (1.8%)
102 (1.4%)
0.03
1,626 (11.6%)
1,657 (11.9%)
-0.01
Lab values- LDL level (mg/dl) (within 3 months) ; 
n (%)
911 (13.6%)
952 (14.2%)
-0.02
71 (1.0%)
61 (0.8%)
0.02
0,982 (7.0%)
1,013 (7.2%)
-0.01
Lab values- LDL level (mg/dl) (within 6 months) ; 
n (%)
1,496 (22.3%)
1,555 (23.2%)
-0.02
130 (1.8%)
102 (1.4%)
0.03
1,626 (11.6%)
1,657 (11.9%)
-0.01
Lab values- NT-proBNP; n (%)
12 (0.2%)
11 (0.2%)
0.00
0 (0.0%)
1 (0.0%)
#DIV/0!
12 (0.1%)
12 (0.1%)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Lab values- NT-proBNP (within 3 months); n (%)
10 (0.1%)
7 (0.1%)
0.00
0 (0.0%)
1 (0.0%)
#DIV/0!
10 (0.1%)
8 (0.1%)
0.00
Lab values- NT-proBNP (within 6 months); n (%)
12 (0.2%)
11 (0.2%)
0.00
0 (0.0%)
1 (0.0%)
#DIV/0!
12 (0.1%)
12 (0.1%)
0.00
Lab values- Total cholesterol (mg/dl) ; n (%)
1,480 (22.1%)
1,514 (22.6%)
-0.01
116 (1.6%)
98 (1.3%)
0.03
1,596 (11.4%)
1,612 (11.5%)
0.00
Lab values- Total cholesterol (mg/dl) (within 3 
months) ; n (%)
899 (13.4%)
912 (13.6%)
-0.01
58 (0.8%)
55 (0.8%)
0.00
0,957 (6.8%)
0,967 (6.9%)
0.00
Lab values- Total cholesterol (mg/dl) (within 6 
months) ; n (%)
1,480 (22.1%)
1,514 (22.6%)
-0.01
116 (1.6%)
98 (1.3%)
0.03
1,596 (11.4%)
1,612 (11.5%)
0.00
Lab values- Triglyceride level (mg/dl); n (%)
1,453 (21.7%)
1,500 (22.4%)
-0.02
117 (1.6%)
94 (1.3%)
0.03
1,570 (11.2%)
1,594 (11.4%)
-0.01
Lab values- Triglyceride level (mg/dl) (within 3 
months); n (%)
881 (13.2%)
906 (13.5%)
-0.01
57 (0.8%)
54 (0.7%)
0.01
0,938 (6.7%)
0,960 (6.9%)
-0.01
Lab values- Triglyceride level (mg/dl) (within 6 
months); n (%)
1,453 (21.7%)
1,500 (22.4%)
-0.02
117 (1.6%)
94 (1.3%)
0.03
1,570 (11.2%)
1,594 (11.4%)
-0.01
Lab result number- HbA1c (%) mean (only 2 to 
20 included) 
                                 1,398                                  1,379 
                                  123                                   100 
0
0
...mean (sd)
7.29 (1.75)
7.27 (1.76)
0.01
8.14 (1.81)
7.66 (1.81)
0.27
7.73 (1.78)
7.47 (1.79)
0.15
...median [IQR]
6.90 [6.00, 8.10]
6.75 [6.00, 8.00]
0.09
8.00 [6.80, 9.20]
7.18 [6.20, 8.95]
0.45
7.47 (1.78)
6.97 (1.79)
0.28
...Missing; n (%)
5,299 (79.1%)
5,318 (79.4%)
-0.01
7,160 (98.3%)
7,183 (98.6%)
-0.02
12,459 (89.1%)
12,501 (89.4%)
-0.01
Lab result number- BNP mean 
                                         87                                          74 
                                     10                                         2 
0
0
...mean (sd)
381.53 (1,230.47)
345.14 (679.13)
0.04
383.62 (605.09)
334.50 (0.71)
0.11
382.62 (957.10)
339.60 (470.04)
0.06
...median [IQR]
94.00 [42.00, 
253.00]
94.50 [44.42, 
276.17]
0.00
163.00 [86.75, 
463.25]
334.50 [334.00, 
335.00]
-0.40
129.95 (957.10)
219.53 (470.04)
-0.12
...Missing; n (%)
6,610 (98.7%)
6,623 (98.9%)
-0.02
7,273 (99.9%)
7,281 (100.0%)
-0.04
13,883 (99.3%)
13,904 (99.5%)
-0.03
Lab result number- BUN (mg/dl) mean 
                                 1,874                                  1,893 
                                  126                                   116 
0
0
...mean (sd)
18.97 (8.52)
18.95 (7.66)
0.00
1,128.51 
(12,470.63)
3,361.89 
(21,189.20)
-0.13
596.99 (9001.01)
1760.48 (15293.87)
-0.09
...median [IQR]
17.00 [14.00, 22.00] 17.00 [14.00, 22.00]
0.00
17.00 [14.00, 
20.75]
17.00 [14.00, 
21.00]
0.00
17.00 (9001.01)
17.00 (15293.87)
0.00
...Missing; n (%)
4,823 (72.0%)
4,804 (71.7%)
0.01
7,157 (98.3%)
7,167 (98.4%)
-0.01
11,980 (85.7%)
11,971 (85.6%)
0.00
Lab result number- Creatinine (mg/dl) mean 
(only 0.1 to 15 included) 
                                 1,913                                  1,927 
                                  121                                   103 
                                2,034                                 2,030 
...mean (sd)
1.09 (0.45)
1.08 (0.40)
0.02
1.01 (0.23)
1.00 (0.24)
0.04
1.05 (0.35)
1.04 (0.33)
0.03
...median [IQR]
1.00 [0.84, 1.21]
1.00 [0.84, 1.22]
0.00
1.00 [0.86, 1.13]
1.00 [0.88, 1.12]
0.00
1.00 (0.35)
1.00 (0.33)
0.00
...Missing; n (%)
4,784 (71.4%)
4,770 (71.2%)
0.00
7,162 (98.3%)
7,180 (98.6%)
-0.02
11,946 (85.5%)
11,950 (85.5%)
0.00
Lab result number- HDL level (mg/dl) mean 
(only =<5000 included) 
                                 1,456                                  1,486 
                                  117                                      96 
                                1,573                                 1,582 
...mean (sd)
46.40 (14.74)
46.63 (14.02)
-0.02
41.80 (11.50)
42.00 (12.11)
-0.02
44.00 (13.15)
44.22 (13.06)
-0.02
...median [IQR]
44.00 [36.00, 54.00] 44.00 [37.00, 54.00]
0.00
41.00 [33.50, 
48.50]
41.00 [35.25, 
48.00]
0.00
42.44 (13.15)
42.44 (13.06)
0.00
...Missing; n (%)
5,241 (78.3%)
5,211 (77.8%)
0.01
7,166 (98.4%)
7,187 (98.7%)
-0.03
12,407 (88.7%)
12,398 (88.7%)
0.00
Lab result number- LDL level (mg/dl) mean (only 
=<5000 included) 
                                 1,463                                  1,522 
                                  111                                      89 
                                1,574                                 1,611 
...mean (sd)
101.93 (45.14)
103.69 (43.77)
-0.04
101.62 (50.86)
96.09 (46.22)
0.11
101.77 (48.20)
99.73 (45.06)
0.04
...median [IQR]
101.00 [75.00, 
128.00]
100.00 [75.00, 
131.00]
0.02
99.00 [69.00, 
134.50]
104.50 [61.00, 
129.00]
-0.11
99.96 (48.20)
102.34 (45.06)
-0.05
...Missing; n (%)
5,234 (78.2%)
5,175 (77.3%)
0.02
7,172 (98.5%)
7,194 (98.8%)
-0.03
12,406 (88.7%)
12,369 (88.5%)
0.01
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Lab result number- Total cholesterol (mg/dl) 
mean (only =<5000 included) 
                                 1,476                                  1,510 
                                  115                                      97 
                                1,591                                 1,607 
...mean (sd)
188.01 (53.70)
187.17 (49.11)
0.02
190.24 (53.63)
187.50 (45.93)
0.05
189.17 (53.66)
187.34 (47.48)
0.04
...median [IQR]
183.00 [153.00, 
214.00]
182.00 [154.00, 
216.00]
0.02
197.00 [148.50, 
230.00]
186.00 [156.50, 
219.25]
0.22
190.29 (53.66)
184.08 (47.48)
0.12
...Missing; n (%)
5,221 (78.0%)
5,187 (77.5%)
0.01
7,168 (98.4%)
7,186 (98.7%)
-0.03
12,389 (88.6%)
12,373 (88.5%)
0.00
Lab result number- Triglyceride level (mg/dl) 
mean (only =<5000 included) 
                                 1,450                                  1,500 
                                  116                                      93 
                                1,566                                 1,593 
...mean (sd)
178.04 (146.67)
171.98 (120.25)
0.05
191.07 (122.18)
207.13 (136.39)
-0.12
184.83 (134.47)
190.29 (128.91)
-0.04
...median [IQR]
143.00 [104.00, 
209.25]
143.50 [104.00, 
203.88]
0.00
163.50 [103.12, 
239.50]
165.00 [122.00, 
245.00]
-0.01
153.68 (134.47)
154.70 (128.91)
-0.01
...Missing; n (%)
5,247 (78.3%)
5,197 (77.6%)
0.02
7,167 (98.4%)
7,190 (98.7%)
-0.03
12,414 (88.8%)
12,387 (88.6%)
0.01
Lab result number- Hemoglobin mean (only >0 
included)
                                 1,451                                  1,430 
                                     97                                      75 
                                1,548                                 1,505 
...mean (sd)
13.81 (1.81)
13.82 (1.78)
-0.01
13.82 (2.15)
135,417.06 
(1,154,595.69)
-0.17
13.82 (1.99)
70553.29 
(833360.19)
-0.12
...median [IQR]
13.90 [12.60, 15.10] 14.00 [12.60, 15.01]
-0.06
14.00 [12.80, 
15.30]
14.10 [13.00, 
15.00]
0.00
13.95 (1.99)
14.05 (833360.19)
0.00
...Missing; n (%)
5,246 (78.3%)
5,267 (78.6%)
-0.01
7,186 (98.7%)
7,208 (99.0%)
-0.03
12,432 (88.9%)
12,475 (89.2%)
-0.01
Lab result number- Serum sodium mean (only > 
90 and < 190 included)
                                 1,869                                  1,891 
                                  133                                   111 
                                2,002                                 2,002 
...mean (sd)
139.98 (2.88)
140.05 (2.79)
-0.02
138.91 (2.64)
139.51 (2.55)
-0.23
139.42 (2.76)
139.77 (2.67)
-0.13
...median [IQR]
140.00 [138.33, 
142.00]
140.00 [138.50, 
142.00]
0.00
139.00 [137.00, 
141.00]
140.00 [138.00, 
141.00]
-0.39
139.48 (2.76)
140.00 (2.67)
-0.19
...Missing; n (%)
4,828 (72.1%)
4,806 (71.8%)
0.01
7,150 (98.2%)
7,172 (98.5%)
-0.02
11,978 (85.7%)
11,978 (85.7%)
0.00
Lab result number- Albumin mean (only >0 and 
<=10 included)
                                 1,708                                  1,714 
                                  115                                      94 
                                1,823                                 1,808 
...mean (sd)
4.19 (0.35)
4.20 (0.34)
-0.03
4.11 (0.54)
4.04 (0.45)
0.14
4.15 (0.46)
4.12 (0.40)
0.07
...median [IQR]
4.20 [4.00, 4.40]
4.20 [4.00, 4.40]
0.00
4.10 [4.00, 4.40]
4.00 [4.00, 4.40]
0.20
4.15 (0.46)
4.10 (0.40)
0.12
...Missing; n (%)
4,989 (74.5%)
4,983 (74.4%)
0.00
7,168 (98.4%)
7,189 (98.7%)
-0.03
12,157 (87.0%)
12,172 (87.1%)
0.00
Lab result number- Glucose (fasting or random) 
mean (only 10-1000 included)
                                 1,858                                  1,885 
                                  133                                   113 
                                1,991                                 1,998 
...mean (sd)
135.97 (63.19)
134.68 (61.29)
0.02
167.91 (62.54)
152.10 (61.99)
0.25
152.61 (62.85)
143.76 (61.66)
0.14
...median [IQR]
114.00 [96.00, 
156.00]
113.00 [97.00, 
151.00]
0.02
153.00 [119.50, 
202.00]
139.00 [110.33, 
179.80]
0.22
134.32 (62.85)
126.54 (61.66)
0.12
...Missing; n (%)
4,839 (72.3%)
4,812 (71.9%)
0.01
7,150 (98.2%)
7,170 (98.4%)
-0.02
11,989 (85.8%)
11,982 (85.7%)
0.00
Lab result number- Potassium mean (only 1-7 
included)
                                 1,914                                  1,926 
                                  124                                   108 
                                2,038                                 2,034 
...mean (sd)
4.44 (0.44)
4.46 (0.44)
-0.05
4.29 (0.48)
4.16 (0.44)
0.28
4.36 (0.46)
4.30 (0.44)
0.13
...median [IQR]
4.40 [4.15, 4.70]
4.40 [4.20, 4.70]
0.00
4.29 [4.00, 4.60]
4.10 [4.00, 4.40]
0.41
4.34 (0.46)
4.24 (0.44)
0.22
...Missing; n (%)
4,783 (71.4%)
4,771 (71.2%)
0.00
7,159 (98.3%)
7,175 (98.5%)
-0.02
11,942 (85.4%)
11,946 (85.5%)
0.00
Comorbidity Scores
CCI (180 days)- ICD9 and ICD10 
...mean (sd)
3.71 (2.43)
3.71 (2.43)
0.00
2.24 (1.64)
2.24 (1.64)
0.00
2.94 (2.06)
2.94 (2.06)
0.00
...median [IQR]
3.00 [2.00, 5.00]
3.00 [2.00, 5.00]
0.00
2.00 [1.00, 3.00]
2.00 [1.00, 3.00]
0.00
2.48 (2.06)
2.48 (2.06)
0.00
Frailty Score (mean): Empirical Version 365 
days, 
...mean (sd)
0.20 (0.05)
0.20 (0.05)
0.00
0.18 (0.04)
0.18 (0.04)
0.00
0.19 (0.05)
0.19 (0.05)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

...median [IQR]
0.19 [0.16, 0.22]
0.19 [0.16, 0.22]
0.00
0.17 [0.15, 0.19]
0.17 [0.15, 0.19]
0.00
0.18 (0.05)
0.18 (0.05)
0.00
Healthcare Utilization
Any hospitalization; n (%)
6,686 (99.8%)
6,690 (99.9%)
-0.03
7,283 (100.0%)
7,283 (100.0%)
#DIV/0!
13,969 (99.9%)
13,973 (99.9%)
0.00
Any hospitalization during prior 31-180 days; n 
(%)
336 (5.0%)
411 (6.1%)
-0.05
176 (2.4%)
192 (2.6%)
-0.01
0,512 (3.7%)
0,603 (4.3%)
-0.03
Endocrinologist Visit; n (%)
464 (6.9%)
450 (6.7%)
0.01
405 (5.6%)
390 (5.4%)
0.01
0,869 (6.2%)
0,840 (6.0%)
0.01
Endocrinologist Visit (30 days prior); n (%)
239 (3.6%)
227 (3.4%)
0.01
198 (2.7%)
210 (2.9%)
-0.01
0,437 (3.1%)
0,437 (3.1%)
0.00
Endocrinologist Visit (31 to 180 days prior); n 
(%)
294 (4.4%)
294 (4.4%)
0.00
253 (3.5%)
234 (3.2%)
0.02
0,547 (3.9%)
0,528 (3.8%)
0.01
Internal medicine/family medicine visits; n (%)
5,736 (85.7%)
5,717 (85.4%)
0.01
5,239 (71.9%)
5,227 (71.8%)
0.00
10,975 (78.5%)
10,944 (78.3%)
0.00
Internal medicine/family medicine visits (30 
days prior) ; n (%)
4,788 (71.5%)
4,783 (71.4%)
0.00
3,320 (45.6%)
3,241 (44.5%)
0.02
8,108 (58.0%)
8,024 (57.4%)
0.01
Internal medicine/family medicine visits (31 to 
180 days prior) ; n (%)
4,341 (64.8%)
4,335 (64.7%)
0.00
4,170 (57.3%)
4,231 (58.1%)
-0.02
8,511 (60.9%)
8,566 (61.3%)
-0.01
Cardiologist visit; n (%)
6,365 (95.0%)
6,231 (93.0%)
0.08
2,849 (39.1%)
2,776 (38.1%)
0.02
9,214 (65.9%)
9,007 (64.4%)
0.03
Number of Cardiologist visits (30 days prior); n 
(%)
6,321 (94.4%)
6,192 (92.5%)
0.08
2,372 (32.6%)
2,275 (31.2%)
0.03
8,693 (62.2%)
8,467 (60.6%)
0.03
Number of Cardiologist visits (31 to 180 days 
prior); n (%)
1,442 (21.5%)
1,466 (21.9%)
-0.01
923 (12.7%)
952 (13.1%)
-0.01
2,365 (16.9%)
2,418 (17.3%)
-0.01
Electrocardiogram ; n (%)
6,294 (94.0%)
6,275 (93.7%)
0.01
4,153 (57.0%)
4,022 (55.2%)
0.04
10,447 (74.7%)
10,297 (73.7%)
0.02
Use of glucose test strips; n (%)
121 (1.8%)
127 (1.9%)
-0.01
106 (1.5%)
102 (1.4%)
0.01
0,227 (1.6%)
0,229 (1.6%)
0.00
Dialysis; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
number of different/distinct medication 
prescriptions
...mean (sd)
10.48 (5.17)
10.46 (5.10)
0.00
9.41 (4.44)
9.33 (4.38)
0.02
9.92 (4.80)
9.87 (4.74)
0.01
...median [IQR]
10.00 [7.00, 13.00]
10.00 [7.00, 13.00]
0.00
9.00 [6.00, 12.00]
9.00 [6.00, 12.00]
0.00
9.48 (4.80)
9.48 (4.74)
0.00
Number of Hospitalizations
...mean (sd)
1.13 (0.42)
1.13 (0.44)
0.00
1.06 (0.27)
1.06 (0.27)
0.00
1.09 (0.35)
1.09 (0.36)
0.00
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 (0.35)
1.00 (0.36)
0.00
Number of hospital days
...mean (sd)
4.37 (3.32)
4.42 (3.60)
-0.01
3.62 (2.00)
3.64 (2.13)
-0.01
3.98 (2.71)
4.01 (2.93)
-0.01
...median [IQR]
3.00 [3.00, 5.00]
3.00 [3.00, 5.00]
0.00
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 (2.71)
3.00 (2.93)
0.00
Number of Emergency Department (ED) visits 
...mean (sd)
1.18 (1.53)
1.19 (1.76)
-0.01
3.37 (5.61)
3.33 (5.97)
0.01
2.32 (4.19)
2.30 (4.48)
0.00
...median [IQR]
1.00 [0.00, 2.00]
1.00 [0.00, 1.00]
0.00
2.00 [0.00, 4.00]
2.00 [0.00, 4.00]
0.00
1.52 (4.19)
1.52 (4.48)
0.00
Number of Office visits
...mean (sd)
4.04 (3.89)
4.00 (3.76)
0.01
3.12 (3.28)
3.09 (3.24)
0.01
3.56 (3.59)
3.53 (3.50)
0.01
...median [IQR]
3.00 [1.00, 6.00]
3.00 [1.00, 6.00]
0.00
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.00
2.48 (3.59)
2.48 (3.50)
0.00
Number of Endocrinologist visits
...mean (sd)
0.29 (1.73)
0.30 (1.91)
-0.01
0.22 (1.30)
0.23 (1.48)
-0.01
0.68 (1.41)
0.69 (1.62)
-0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.48 (1.41)
0.48 (1.62)
0.00
Number of internal medicine/family medicine 
visits
...mean (sd)
9.83 (13.95)
9.77 (13.26)
0.00
4.68 (7.55)
4.58 (7.32)
0.01
7.15 (11.09)
7.07 (10.59)
0.01
...median [IQR]
6.00 [2.00, 12.00]
6.00 [2.00, 12.00]
0.00
2.00 [0.00, 6.00]
2.00 [0.00, 6.00]
0.00
3.92 (11.09)
3.92 (10.59)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Number of Cardiologist visits
...mean (sd)
9.71 (7.61)
9.65 (6.80)
0.01
1.28 (2.49)
1.30 (2.66)
-0.01
5.32 (5.57)
5.30 (5.08)
0.00
...median [IQR]
9.00 [6.00, 12.00]
9.00 [6.00, 12.00]
0.00
0.00 [0.00, 2.00]
0.00 [0.00, 2.00]
0.00
4.31 (5.57)
4.31 (5.08)
0.00
Number electrocardiograms received 
...mean (sd)
3.62 (3.22)
3.57 (3.02)
0.02
1.13 (1.46)
1.10 (1.48)
0.02
2.32 (2.47)
2.28 (2.35)
0.02
...median [IQR]
3.00 [2.00, 5.00]
3.00 [2.00, 5.00]
0.00
1.00 [0.00, 2.00]
1.00 [0.00, 2.00]
0.00
1.96 (2.47)
1.96 (2.35)
0.00
Number of HbA1c tests ordered
...mean (sd)
0.56 (0.81)
0.55 (0.79)
0.01
0.34 (0.66)
0.32 (0.63)
0.03
0.45 (0.74)
0.43 (0.71)
0.03
...median [IQR]
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.74)
0.00 (0.71)
0.00
Number of glucose tests ordered
...mean (sd)
0.27 (1.06)
0.31 (2.85)
-0.02
0.14 (0.58)
0.16 (0.99)
-0.02
0.20 (0.84)
0.23 (2.10)
-0.02
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.84)
0.00 (2.10)
0.00
Number of lipid tests ordered
...mean (sd)
0.61 (0.81)
0.61 (0.80)
0.00
0.44 (0.88)
0.43 (0.85)
0.01
0.52 (0.85)
0.52 (0.83)
0.00
...median [IQR]
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 (0.85)
0.00 (0.83)
0.00
Number of creatinine tests ordered
...mean (sd)
0.06 (0.29)
0.06 (0.34)
0.00
0.04 (0.24)
0.04 (0.23)
0.00
0.05 (0.27)
0.05 (0.29)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.27)
0.00 (0.29)
0.00
Number of BUN tests ordered
...mean (sd)
0.03 (0.22)
0.04 (0.27)
-0.04
0.02 (0.16)
0.02 (0.17)
0.00
0.02 (0.19)
0.03 (0.22)
-0.05
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.19)
0.00 (0.22)
0.00
Number of tests for microalbuminuria
...mean (sd)
0.33 (0.81)
0.33 (0.81)
0.00
0.17 (0.58)
0.15 (0.54)
0.04
0.25 (0.70)
0.24 (0.68)
0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.70)
0.00 (0.68)
0.00
Total N distinct ICD9/ICD10 diagnoses at the 
3rd digit level 
...mean (sd)
13.25 (11.46)
13.42 (11.51)
-0.01
7.61 (8.40)
7.68 (8.58)
-0.01
10.31 (9.98)
10.43 (10.09)
-0.01
...median [IQR]
12.00 [4.00, 19.00]
12.00 [4.00, 20.00]
0.00
4.00 [0.00, 14.00]
4.00 [0.00, 14.00]
0.00
7.83 (9.98)
7.83 (10.09)
0.00
For PS
Hemorrhagic stroke+Other cerebrovascular 
disease+Cerebrovascular procedure (for PS); n 
(%)
155 (2.3%)
163 (2.4%)
-0.01
78 (1.1%)
77 (1.1%)
0.00
233 (1.7%)
240 (1.7%)
0.00
Occurrence of creatinine tests ordered (for PS); 
n (%)
299 (4.5%)
291 (4.3%)
0.01
204 (2.8%)
211 (2.9%)
-0.01
0,503 (3.6%)
0,502 (3.6%)
0.00
Occurrence of BUN tests ordered (for PS); n (%)
168 (2.5%)
167 (2.5%)
0.00
115 (1.6%)
117 (1.6%)
0.00
0,283 (2.0%)
0,284 (2.0%)
0.00
Occurrence of chronic renal insufficiency w/o 
CKD (for PS) ; n (%)
704 (10.5%)
682 (10.2%)
0.01
244 (3.4%)
229 (3.1%)
0.02
0,948 (6.8%)
0,911 (6.5%)
0.01
Chronic kidney disease Stage 1-2 (for PS); n (%)
290 (4.3%)
267 (4.0%)
0.02
72 (1.0%)
72 (1.0%)
0.00
362 (2.6%)
339 (2.4%)
0.01
Chronic kidney disease Stage 3-6 (for PS); n (%)
1,070 (16.0%)
1,060 (15.8%)
0.01
340 (4.7%)
337 (4.6%)
0.00
1,410 (10.1%)
1,397 (10.0%)
0.00
Bladder stones+Kidney stones (for PS); n (%)
224 (3.3%)
209 (3.1%)
0.01
133 (1.8%)
122 (1.7%)
0.01
0,357 (2.6%)
0,331 (2.4%)
0.01
Diabetes with peripheral circulatory 
disorders+Gangrene+Osteomyelitis(for PS)  with 
ICD10 ; n (%)
464 (6.9%)
464 (6.9%)
0.00
147 (2.0%)
144 (2.0%)
0.00
0,611 (4.4%)
0,608 (4.3%)
0.00
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

Alcohol abuse or dependence+Drug abuse or 
dependence (for PS); n (%)
331 (4.9%)
334 (5.0%)
0.00
186 (2.6%)
200 (2.7%)
-0.01
517 (3.7%)
534 (3.8%)
-0.01
Diabetes with other ophthalmic 
manifestations+Retinal detachment, vitreous 
hemorrhage, vitrectomy+Retinal laser 
coagulation therapy (for PS); n (%)
67 (1.0%)
70 (1.0%)
0.00
106 (1.5%)
99 (1.4%)
0.01
0,173 (1.2%)
0,169 (1.2%)
0.00
Other atherosclerosis+Cardiac conduction 
disorders+Other CVD (for PS)  ; n (%)
3,094 (46.2%)
3,129 (46.7%)
-0.01
2,466 (33.9%)
2,510 (34.5%)
-0.01
5,560 (39.8%)
5,639 (40.3%)
-0.01
Previous cardiac procedure (CABG or PTCA or 
Stent) + History of CABG or PTCA (for PS) ; n (%)
6,322 (94.4%)
6,349 (94.8%)
-0.02
6,693 (91.9%)
6,665 (91.5%)
0.01
13,015 (93.1%)
13,014 (93.1%)
0.00
Hyperthyroidism + Hypothyroidism + Other 
disorders of thyroid gland (for PS); n (%)
1,250 (18.7%)
1,239 (18.5%)
0.01
816 (11.2%)
838 (11.5%)
-0.01
2,066 (14.8%)
2,077 (14.9%)
0.00
Delirium + Psychosis (for PS); n (%)
213 (3.2%)
202 (3.0%)
0.01
92 (1.3%)
91 (1.2%)
0.01
305 (2.2%)
293 (2.1%)
0.01
Any use of Meglitinides (for PS); n (%)
23 (0.3%)
21 (0.3%)
0.00
18 (0.2%)
29 (0.4%)
-0.04
41 (0.3%)
50 (0.4%)
-0.02
Any use of AGIs (for PS); n (%)
9 (0.1%)
7 (0.1%)
0.00
2,466 (33.9%)
2,510 (34.5%)
-0.01
5,560 (39.8%)
5,639 (40.3%)
-0.01
CKD stage 3-6 + dialysis (for PS); n (%)
1,070 (16.0%)
1,060 (15.8%)
0.01
340 (4.7%)
337 (4.6%)
0.00
1,410 (10.1%)
1,397 (10.0%)
0.00
Use of thiazide; n (%)
654 (9.8%)
645 (9.6%)
0.01
604 (8.3%)
592 (8.1%)
0.01
12,367 (88.5%)
12,391 (88.6%)
0.00
Use of beta blockers; n (%)
5,881 (87.8%)
5,895 (88.0%)
-0.01
6,486 (89.1%)
6,496 (89.2%)
0.00
3,384 (24.2%)
3,397 (24.3%)
0.00
Use of calcium channel blockers; n (%)
1,824 (27.2%)
1,833 (27.4%)
0.00
1,560 (21.4%)
1,564 (21.5%)
0.00
4,418 (31.6%)
4,404 (31.5%)
0.00
All antidiabetic medications except Insulin; n 
(%)
2,329 (34.8%)
2,328 (34.8%)
0.00
2,089 (28.7%)
2,076 (28.5%)
0.00
1,258 (9.0%)
1,237 (8.8%)
0.01
DM Medications - Insulin ; n (%)
1,033 (15.4%)
988 (14.8%)
0.02
917 (12.6%)
873 (12.0%)
0.02
1,950 (13.9%)
1,861 (13.3%)
0.02
Use of Low Intensity Statins; n (%)
1,915 (28.6%)
1,953 (29.2%)
-0.01
2,002 (27.5%)
2,035 (27.9%)
-0.01
3917 (28.0%)
3,988 (28.5%)
-0.01
Use of High Intensity Statins; n (%)
4,845 (72.3%)
5,032 (75.1%)
-0.06
5,324 (73.1%)
5,519 (75.8%)
-0.06
10169 (72.7%)
10,551 (75.5%)
-0.06
Malignant hypertension; n (%)
283 (4.2%)
317 (4.7%)
-0.02
2,690 (36.9%)
2,670 (36.7%)
0.00
2973 (21.3%)
2,987 (21.4%)
0.00
Cardiovascular stress test; n (%)
19 (0.3%)
18 (0.3%)
0.00
14 (0.2%)
17 (0.2%)
0.00
0,033 (0.2%)
35 (0.3%)
-0.02
Echocardiogram; n (%)
5,122 (76.5%)
5,169 (77.2%)
-0.02
5,207 (71.5%)
5,195 (71.3%)
0.00
10,329 (73.9%)
10364 (74.1%)
0.00
Number of BNP tests
...mean (sd)
0.11 (0.43)
0.12 (0.45)
-0.02
0.13 (0.42)
0.12 (0.38)
0.02
0.12 (0.42)
0.12 (0.42)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.42)
0.00 (0.42)
0.00
Number of Cardiac biomarkers tests (tropnin, 
CK-MBs, Myoglobin, CPK)
...mean (sd)
0.61 (1.83)
0.60 (1.85)
0.01
0.68 (1.49)
0.66 (1.59)
0.01
0.65 (1.66)
0.63 (1.72)
0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 (1.66)
0.00 (1.72)
0.00
Number of Ambulatory Blood pressure 
monitoring tests
...mean (sd)
0.00 (0.02)
0.00 (0.02)
0.00
0.00 (0.03)
0.00 (0.02)
0.00
0.00 (0.03)
0.00 (0.02)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.03)
0.00 (0.02)
0.00
N of days on antihypertensive medications 
during baseline
...mean (sd)
100.13 (78.50)
101.32 (78.10)
-0.02
85.98 (79.37)
85.78 (79.72)
0.00
92.76 (78.95)
93.22 (78.95)
-0.01
...median [IQR]
135.00 [1.00, 
178.00]
137.00 [1.00, 
178.00]
-0.03
89.00 [1.00, 
173.00]
88.00 [1.00, 
174.00]
0.01
111.04 (78.95)
111.47 (78.95)
-0.01
N of days in database anytime prior
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

...mean (sd)
1,800.74 (1,442.20) 1,791.98 (1,450.03)
0.01
2,250.83 
(1,484.36)
2,264.37 
(1,484.25)
-0.01
2035.22 (1464.32)
2038.08 (1467.96)
0.00
...median [IQR]
1,342.00 [646.00, 
2,614.00]
1,327.00 [641.50, 
2,621.50]
0.01
1,996.00 [941.00, 
3,521.00]
1,990.00 [966.00, 
3,538.00]
0.00
1682.71 (1464.32)
1672.40 (1467.96)
0.01
Mean Copay for per prescription cost (charges 
in U.S. $) (180-1 day prior)
...mean (sd)
22.65 (29.77)
22.98 (32.80)
-0.01
16.54 (20.34)
16.64 (21.51)
0.00
19.47 (25.30)
19.68 (27.50)
-0.01
...median [IQR]
13.37 [5.00, 30.00]
13.80 [5.01, 29.28]
-0.01
10.61 [2.74, 23.07] 10.96 [3.67, 22.35]
-0.02
11.93 (25.30)
12.32 (27.50)
-0.01
...Missing; n (%)
579 (8.6%)
581 (8.7%)
0.00
850 (11.7%)
891 (12.2%)
-0.02
1,429 (10.2%)
1472 (10.5%)
-0.01
Colonos; n (%)
254 (3.8%)
266 (4.0%)
-0.01
263 (3.6%)
250 (3.4%)
0.01
0,517 (3.7%)
516 (3.7%)
0.00
Fecal occult blood (FOB) test; n (%)
196 (2.9%)
192 (2.9%)
0.00
160 (2.2%)
164 (2.3%)
-0.01
0,356 (2.5%)
356 (2.5%)
0.00
Flu vaccine; n (%)
974 (14.5%)
1,032 (15.4%)
-0.03
646 (8.9%)
637 (8.7%)
0.01
1,620 (11.6%)
1669 (11.9%)
-0.01
Mammogram; n (%)
422 (6.3%)
439 (6.6%)
-0.01
277 (3.8%)
298 (4.1%)
-0.02
0,699 (5.0%)
737 (5.3%)
-0.01
Pap smear; n (%)
104 (1.6%)
103 (1.5%)
0.01
118 (1.6%)
125 (1.7%)
-0.01
0,222 (1.6%)
228 (1.6%)
0.00
Pneumonia vaccine; n (%)
1,207 (18.0%)
1,261 (18.8%)
-0.02
624 (8.6%)
622 (8.5%)
0.00
1,831 (13.1%)
1883 (13.5%)
-0.01
PSA test or Prostate exam for DRE; n (%)
963 (14.4%)
952 (14.2%)
0.01
792 (10.9%)
802 (11.0%)
0.00
1,755 (12.6%)
1754 (12.5%)
0.00
Bone mineral density; n (%)
157 (2.3%)
163 (2.4%)
-0.01
79 (1.1%)
78 (1.1%)
0.00
0,236 (1.7%)
241 (1.7%)
0.00
Use of Sympatomimetic agents; n (%)
38 (0.6%)
43 (0.6%)
0.00
79 (1.1%)
80 (1.1%)
0.00
0,117 (0.8%)
123 (0.9%)
-0.01
Use of CNS stimulants; n (%)
17 (0.3%)
23 (0.3%)
0.00
38 (0.5%)
42 (0.6%)
-0.01
0,055 (0.4%)
65 (0.5%)
-0.01
Use of estrogens, progestins, androgens; n (%)
204 (3.0%)
180 (2.7%)
0.02
287 (3.9%)
298 (4.1%)
-0.01
0,491 (3.5%)
478 (3.4%)
0.01
Use of Angiogenesis inhibitors; n (%)
8 (0.1%)
5 (0.1%)
0.00
0 (0.0%)
1 (0.0%)
#DIV/0!
0,008 (0.1%)
6 (0.0%)
0.04
Use of Oral Immunosuppressants; n (%)
16 (0.2%)
15 (0.2%)
0.00
22 (0.3%)
19 (0.3%)
0.00
0,038 (0.3%)
34 (0.2%)
0.02
Use of fondaparinux or Bivalirudin; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0,000 (0.0%)
0 (0.0%)
#DIV/0!
Use of other direct thrombin inhibitors 
(lepirudin, desirudin, argatroban); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0,000 (0.0%)
0 (0.0%)
#DIV/0!
Use of Prasugrel ON CED; n (%)
22 (0.3%)
29 (0.4%)
-0.02
34 (0.5%)
33 (0.5%)
0.00
0,056 (0.4%)
62 (0.4%)
0.00
Use of Prasugrel 180 to 1 day prior; n (%)
47 (0.7%)
61 (0.9%)
-0.02
56 (0.8%)
52 (0.7%)
0.01
0,103 (0.7%)
113 (0.8%)
-0.01
Duration of index hospitalization (i.e. anchor 
hospitalization LOS)
...mean (sd)
3.97 (2.97)
4.01 (3.08)
-0.01
3.40 (1.60)
3.43 (1.62)
-0.02
3.67 (2.36)
3.71 (2.43)
-0.02
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 [2.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 (2.36)
3.00 (2.43)
0.00
Number of D-dimer tests
...mean (sd)
0.04 (0.22)
0.04 (0.23)
0.00
0.05 (0.24)
0.06 (0.26)
-0.04
0.05 (0.23)
0.05 (0.25)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.23)
0.00 (0.25)
0.00
Numbe of CRP, high-sensitivity CRP tests
...mean (sd)
0.06 (0.31)
0.06 (0.31)
0.00
0.04 (0.27)
0.04 (0.26)
0.00
0.05 (0.29)
0.05 (0.29)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.29)
0.00 (0.29)
0.00
Number of PT or aPTTt tests
...mean (sd)
0.41 (1.41)
0.41 (1.40)
0.00
0.39 (0.97)
0.38 (1.01)
0.01
0.40 (1.20)
0.39 (1.21)
0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (1.20)
0.00 (1.21)
0.00
Number of Bleeding time tests
...mean (sd)
0.00 (0.04)
0.00 (0.02)
0.00
0.00 (0.01)
0.00 (0.01)
0.00
0.00 (0.03)
0.00 (0.02)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.03)
0.00 (0.02)
0.00
HAS-BLED Score (ICD-9 and ICD-10), 180 days
...mean (sd)
3.91 (0.75)
3.92 (0.74)
-0.01
3.40 (0.61)
3.40 (0.60)
0.00
3.64 (0.68)
3.65 (0.67)
-0.01
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg

...median [IQR]
4.00 [3.00, 4.00]
4.00 [3.00, 4.00]
0.00
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.48 (0.68)
3.48 (0.67)
0.00
Drug eluting stent; n (%)
1,231 (18.4%)
1,211 (18.1%)
0.01
2,311 (31.7%)
2,256 (31.0%)
0.02
3,542 (25.3%)
3467 (24.8%)
0.01
Bare metal stent; n (%)
5,572 (83.2%)
5,570 (83.2%)
0.00
6,125 (84.1%)
6,043 (83.0%)
0.03
11,697 (83.7%)
11613 (83.1%)
0.02
Use of CYP inhibitors; n (%)
1,377 (20.6%)
1,380 (20.6%)
0.00
1,243 (17.1%)
1,220 (16.8%)
0.01
2,620 (18.7%)
2600 (18.6%)
0.00
Use of CYP inducers; n (%)
7 (0.1%)
6 (0.1%)
0.00
10 (0.1%)
8 (0.1%)
0.00
0,017 (0.1%)
14 (0.1%)
0.00
Commercial vs Medicare Advantage- Business 
Type Code - CORRECT ONE - TRUVEN
...Commercial; n (%)
1,994 (29.8%)
1,995 (29.8%)
0.00
2,433 (33.4%)
2,455 (33.7%)
-0.01
4,427 (31.7%)
4450 (31.8%)
0.00
...Medicare Advantage; n (%)
4,703 (70.2%)
4,702 (70.2%)
0.00
4,850 (66.6%)
4,828 (66.3%)
0.01
9,553 (68.3%)
9530 (68.2%)
0.00
Commercial vs Medicare Advantage- Business 
Type Code
...COM = COMMERCIAL; n (%)
1,994 (29.8%)
1,995 (29.8%)
0.00
-
-
#VALUE!
1,994 (29.8%)
1,995 (29.8%)
0.00
...MCR = MEDICARE; n (%)
4,703 (70.2%)
4,702 (70.2%)
0.00
-
-
#VALUE!
4,703 (70.2%)
4,702 (70.2%)
0.00
...MCD = MEDICAID; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...NONE = NO BUSINESS LINE CODE (added in 
2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
Commercial vs Medicare Advantage- Data Type
...1 - Fee For Service; n (%)
-
-
#VALUE!
4,383 (60.2%)
4,356 (59.8%)
0.01
4,383 (60.2%)
4,356 (59.8%)
0.01
...2 - Encounter; n (%)
-
-
#VALUE!
467 (6.4%)
472 (6.5%)
0.00
467 (6.4%)
472 (6.5%)
0.00
...3 - Medicare; n (%)
-
-
#VALUE!
2,169 (29.8%)
2,198 (30.2%)
-0.01
2,169 (29.8%)
2,198 (30.2%)
-0.01
...4 - Medicare Encounter; n (%)
-
-
#VALUE!
264 (3.6%)
257 (3.5%)
0.01
264 (3.6%)
257 (3.5%)
0.01
Metropolitan Statistical Area - Urban (any MSA) 
vs Rural (non-MSA)
...Urban; n (%)
-
-
#VALUE!
5,129 (70.4%)
5,146 (70.7%)
-0.01
5,129 (70.4%)
5,146 (70.7%)
-0.01
...Rural; n (%)
-
-
#VALUE!
559 (7.7%)
533 (7.3%)
0.02
559 (7.7%)
533 (7.3%)
0.02
...Unknown/Missing; n (%)
-
-
#VALUE!
1,595 (21.9%)
1,604 (22.0%)
0.00
1,595 (21.9%)
1,604 (22.0%)
0.00
N of Generic name drugs
...mean (sd)
16.07 (12.36)
15.97 (13.43)
0.01
12.49 (8.99)
12.30 (9.86)
0.020138
14.20 (10.74)
14.06 (11.71)
0.01
...median [IQR]
13.00 [8.00, 21.00]
13.00 [7.00, 21.00]
0.00
10.00 [6.00, 16.00] 10.00 [5.00, 16.00]
0
11.44 (10.74)
11.44 (11.71)
0.00
N of Brand name drugs
...mean (sd)
3.76 (5.67)
3.73 (4.17)
0.01
3.65 (5.13)
3.63 (3.53)
0.00
3.70 (5.40)
3.68 (3.85)
0.07
...median [IQR]
1.00 [0.00, 5.00]
2.00 [1.00, 5.00]
-0.20
2.00 [0.00, 5.00]
2.00 [1.00, 5.00]
0
1.52 (5.40)
2.00 (3.85)
0.07
Table 1: Ticagrelor 90 mg vs Clopidogrel 75 mg